[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20110257380A1 - Glycomimetic replacements for hexoses and n-acetyl hexosamines - Google Patents

Glycomimetic replacements for hexoses and n-acetyl hexosamines Download PDF

Info

Publication number
US20110257380A1
US20110257380A1 US13/093,611 US201113093611A US2011257380A1 US 20110257380 A1 US20110257380 A1 US 20110257380A1 US 201113093611 A US201113093611 A US 201113093611A US 2011257380 A1 US2011257380 A1 US 2011257380A1
Authority
US
United States
Prior art keywords
alkanyl
fuc
aryl
alkynyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/093,611
Inventor
Beat Ernst
Daniel Schwizer
Arun K. Sarkar
John L. Magnani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycomimetics Inc
Original Assignee
Glycomimetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomimetics Inc filed Critical Glycomimetics Inc
Priority to US13/093,611 priority Critical patent/US20110257380A1/en
Publication of US20110257380A1 publication Critical patent/US20110257380A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates generally to compounds and methods for obtaining oligosaccharide mimics, and more particularly for obtaining oligosaccharide mimics by incorporating or substituting in a cyclohexane derivative.
  • Naturally occurring monosaccharides and oligosaccharides play a role, or are capable of playing a role, in a variety of biological processes.
  • non-naturally occurring monosaccharides and oligosaccharides may serve to replace or even improve upon their naturally occurring counterparts.
  • Monosaccharides and particularly oligosaccharides may be difficult, and thus costly, to produce. Even where the degree of difficulty to produce is not particularly elevated, the production of monosaccharides and oligosaccharides may still nevertheless be costly. This problem is multiplied where a costly monosaccharide or oligosaccharide needs to be mass produced. While mimics of monosaccharides and oligosaccharides (“glycomimetics”) may improve upon their biological properties, the cost of producing the mimics may not be significantly reduced relative to that which they mimic.
  • the invention provides compounds and methods for obtaining oligosaccharide mimics.
  • a method for preparing an oligosaccharide mimic comprising incorporating at least one cyclohexane derivative into an oligosaccharide or glycomimetic compound, wherein the cyclohexane derivative has the formula:
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R 1 or R 2 . Also included are products prepared by the method.
  • a method for substituting a monosaccharide mimic for at least one hexose or hexosamine in an oligosaccharide compound or glycomimetic compound or in an oligosaccharide or glycomimetic of an oligosaccharide-containing or glycomimetic-containing compound comprising replacing at least one hexose or hexosamine in an oligosaccharide or glycomimetic compound with a cyclohexane derivative, wherein the cyclohexane derivative has the formula:
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R 1 or R 2 . Also included are products prepared by the method.
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R 1 or R 2 .
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • “another of the compound” refers to either a second compound identical to the first compound, or a second compound that is encompassed by the disclosure herein but not identical to the first compound.
  • the present invention provides a compound consisting of:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • Me is methyl and Bz is benzoyl.
  • the compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • Me is methyl and Bz is benzoyl.
  • the compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • Me is methyl and Bz is benzoyl.
  • the compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • Me is methyl and Bz is benzoyl.
  • the compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • FIG. 1 is a diagram illustrating the synthesis of GlcNAc mimics from tetrahydrophthalic anhydride.
  • FIG. 2 is a diagram illustrating the synthesis of GlcNAc mimics from cyclohexenon.
  • FIG. 3 is a diagram illustrating the synthesis of mimics.
  • FIG. 4 is a diagram illustrating the synthesis of mimics.
  • FIG. 5 is a diagram illustrating the synthesis of mimics.
  • FIG. 6 is a diagram illustrating the synthesis of mimics.
  • FIG. 8 is a diagram illustrating the synthesis of mimics.
  • FIG. 10 is a diagram illustrating the synthesis of a pegylated mimic.
  • FIG. 11 is a diagram illustrating the synthesis of a pegylated tetramer of a mimic.
  • FIG. 13 is a diagram illustrating the synthesis of mimics.
  • the present invention provides compounds and methods for obtaining monosaccharide and oligosaccharide mimics.
  • Such mimics have a variety of uses in vitro and in vivo, including as antagonists of E-selectin.
  • an oligosaccharide mimic may be prepared by incorporating one or more cyclohexane derivatives into an oligosaccharide or glycomimetic compound.
  • An oligosaccharide refers to two or more monosaccharides covalently joined. Oligosaccharides are polymers containing monosaccharide units, typically with 2 to about 100 monosaccharides and any integer in-between. Each monosaccharide of an oligosaccharide is independently selected; although two or more monosaccharides may be identical.
  • the cyclohexane derivative of the methods of the present invention has the formula:
  • R 1 may be H, C 1 -C 8 alkanyl, C 1 -C 8 alkenyl, C 1 -C 8 alkynyl, halogenated C 1 -C 8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X ⁇ H, C 1 -C 8 alkanyl, C 1 -C 8 alkenyl, C 1 -C 8 alkynyl, halogenated C 1 -C 8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C( ⁇ O)OX, alkanyl substituted with C( ⁇ O)OX, C( ⁇ O)NHX, alkanyl substituted with C( ⁇ O)NHX, where X ⁇ C 1 -C 8 alkanyl, C 1 -C 8 alkenyl, C 1
  • the cyclohexane derivative is attached to the oligosaccharide or glycomimetic compound at least at one of the OH, the R 1 or the R 2 .
  • attachment is at least at one of the OH or the R 2 .
  • Other options for attachment include at both of the OH, e.g., one monosaccharide or monosaccharide mimic attached at one of the OH and another monosaccharide or monosaccharide mimic attached at the other OH.
  • a “C 1 -C 8 alkanyl” refers to an alkane substituent with one to eight carbon atoms and may be straight chain, branched or cyclic (cycloalkanyl). Examples are methyl, ethyl, propyl, isopropyl, butyl and t-butyl.
  • a “halogenated C 1 -C 8 alkanyl” refers to a “C 1 -C 8 alkanyl” possessing at least one halogen. Where there is more than one halogen present, the halogens present may be the same or different or both (if at least three present).
  • a “C 1 -C 8 alkenyl” refers to an alkene substituent with one to eight carbon atoms, at least one carbon-carbon double bond, and may be straight chain, branched or cyclic (cycloalkenyl). Examples are similar to “C 1 -C 8 alkanyl” examples except possessing at least one carbon-carbon double bond.
  • a “C 1 -C 8 alkynyl” refers to an alkyne substituent with one to eight carbon atoms, at least one carbon-carbon triple bond, and may be straight chain, branched or cyclic (cycloalkynyl). Examples are similar to “C 1 -C 8 alkanyl” examples except possessing at least one carbon-carbon triple bond.
  • Me and Et represent methyl and ethyl, respectively.
  • Bz represents benzoyl.
  • Ar represents aryl.
  • physiologically acceptable salts include Na, K, Li, Mg and Ca.
  • Monosaccharide substituents recited herein e.g., D-mannose, L-galactose, D-arabinose and L-fucose may be in the furanose, pyranose or open form.
  • a linker arm may be desirable for attachment, for example, to a monosaccharide, a monosaccharide mimic or something else such as an amino acid, nucleic acid or lipid.
  • a linker may include a spacer group, such as —(CH 2 ) n — or —O(CH 2 ) n — where n is generally about 1-20 (all number ranges disclosed herein include any whole integer range therein).
  • An example of a linker is —NH 2 , e.g., —CH 2 —NH 2 when it includes a short spacer group.
  • linkers with or without a spacer group e.g., CONH(CH 2 ) 2 NH 2 , COOMe, or polyethylene glycol or derivative
  • linkers with or without a spacer group e.g., CONH(CH 2 ) 2 NH 2 , COOMe, or polyethylene glycol or derivative
  • a cyclohexane derivative may be attached at one or both OH.
  • R 2 is defined as above;
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R 1 or R 2 .
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • the present invention provides a compound having the formula:
  • the present invention provides a compound having the formula:
  • the compound may include a polyethylene glycol attached thereto.
  • multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • a polyethylene glycol (PEG), including derivatives thereof, may be attached to a compound.
  • PEG polyethylene glycol
  • multimers of the same compound or different compounds of the compounds described herein i.e., two or more compounds joined to one another
  • PEG polyethylene glycol
  • Examples of particular compounds amenable to the attachment of a PEG or to the formation of a multimer including PEG, are disclosed above as embodiments of the present invention.
  • Procedures for preparing a pegylated compound or pegylated multimers will be familiar to those in the art or in possession of the present disclosure. Examples are depicted in FIG. 10 (a pegylated compound) and FIG. 11 (a pegylated tetramer).
  • Acid IV (8.30 g, 65.7 mmol) was placed in a flask purged with argon and suspended in water (180 ml). The reaction mixture was cooled down to 0° C. and NaHCO 3 (16.6 g, 197 mmol) was added, followed by a solution of KI (65.4 g, 394 mmol) and iodine (17.5 g, 68.9 mmol) in water (150 ml). The reaction was stirred at r.t. for 24 h and then extracted three times with CH 2 Cl 2 (3 ⁇ 60 ml). The combined organic layers were washed with a solution of Na 2 S 2 O 3 (50 g) in water (250 ml).
  • Iodolactone V (15.73 g, 62.2 mmol) was dissolved in dry THF (340 ml). Then DBU (14 ml, 93.3 mmol) was added and the mixture was refluxed for 20 h (TLC-control:petroleum ether/Et 2 O, 1:1). The reaction mixture was cooled down to r.t., transferred with Et 2 O (200 ml) into a separation funnel and extracted with aqueous HCl (400 ml, 0.5 M) and brine (400 ml). The aqueous layers were extracted three times with Et 2 O (3 ⁇ 200 ml). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuo (350 mbar).
  • the reaction mixture was diluted with CH 2 Cl 2 (50 ml) and washed twice with HCl 3% (2 ⁇ 50 ml).
  • the aqueous layers were extracted with CH 2 Cl 2 (2 ⁇ 25 ml) and the combined organic layers were washed with a mixture of brine (80 ml) and water (100 ml).
  • the layers were separated and the aqueous layer was extracted with CH 2 Cl 2 (2 ⁇ 50 ml).
  • the combined organic layers were concentrated in vacuo to afford a brown residue still dissolved in a few ml of CH 2 Cl 2 , and was then treated with activated charcoal and filtered through celite. The clear green mixture was concentrated to dryness.
  • Tritylether XVII (948 mg, 2.79 mmol) was dissolved under argon atmosphere in CH 2 Cl 2 (30 ml) and NaHCO 3 (281 mg, 3.34 mmol) was added. The mixture was cooled to 0° C. and under stirring m-chloroperbenzoic acid (70%, 960 mg, 5.56 mmol) was added. After stirring for 1.5 h the reaction temperature was gradually raised to room temperature and the mixture was stirred for another 3.5 h. The reaction was diluted with CH 2 Cl 2 (50 ml) and transferred to a separation funnel. The excess of m-chloroperbenzoic acid was destroyed by washing with satd. solution of Na 2 S 2 O 3 (2 ⁇ 150 ml).
  • Copper(I) iodide (99 mg, 2.62 mmol) was dried at high vacuo at 200° C. for 30 minutes, then flushed with argon and suspended in dry diethylether (10 ml). After cooling to ⁇ 20° C. MeLi (1.6 M in ether, 3.26 ml, 5.22 mmol) was slowly added and the solution was stirred for 15 minutes. A solution of epoxide anti-XVIII (310 mg, 0.870 mmol) in diethylether (7 ml) was added to the cuprate. After stirring for 30 minutes at ⁇ 20° C. the reaction mixture was slowly brought to room temperature and stirred for one week.
  • the reaction was diluted with tert-butyl methyl ether (10 ml) and quenched at 0° C. with satd. solution of NaHCO 3 (10 ml).
  • the reaction mixture was further diluted and extracted with tert-butyl methyl ether and satd. solution of NaHCO 3 (each 20 ml).
  • the aqueous layer was extracted twice with tert-butyl methyl ether (2 ⁇ 50 ml).
  • the combined organic layers were dried with Na 2 SO 4 and concentrated.
  • the residue was purified by flash chromatography (petroleum ether/EtOAc/Et 3 N, 13:1:0.07) to yield XIX (206 mg, 64%) as yellowish resin.
  • a vinyl lithium solution was generated in situ by treating a solution of tetravinyl tin (409 ⁇ L, 2.25 mmol) in THF (3 mL) with nBuLi (2.5 M in hexane, 3.35 mL, 8.38 mmol) during 30 min at 0° C.
  • CuCN (373 mg, 4.16 mmol) in THF (8 mL) was treated with the vinyl lithium solution and BF 3 etherate (209 ⁇ L, 1.66 mmol) in THF (1.5 mL) according to general procedure A.
  • Epoxide A-I (296 mg, 0.830 mmol) in THF (8 mL) was slowly added and the reaction slowly warmed to ⁇ 30° C.
  • thioglycoside A-VI (112 mg, 0.144 mmol) and glycosyl acceptor A-V (61.6 mg, 0.110 mmol) in dry CH 2 Cl 2 (4 mL) were added via syringe to activated 3 ⁇ molecular sieves (1 g).
  • a suspension of DMTST (87.0 mg, 0.337 mmol) and activated 3 ⁇ molecular sieves (500 mg) in CH 2 Cl 2 (2 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH 2 Cl 2 (1 mL). The reaction was stopped after 49.5 h and work-up and purification according to general procedure C afforded A-VII (110 mg, 78%) as a colorless foam.
  • A-VII (38.2 mg, 29.9 ⁇ mol) was hydrogenated with Pd(OH) 2 /C (50 mg, 10% Pd) in dioxane/H 2 O (4:1, 3.75 mL) according to general procedure D. After 24 h the reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (74.6 ⁇ mol in 73 ⁇ l MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (8.5 ⁇ L). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford A-VIII (16.3 mg, 77%) as a colorless solid.
  • a cPrLi solution was generated in situ by treating a solution of bromocyclopropane (370 ⁇ L, 4.63 mmol) in THF (4 mL) with tBuLi (1.7 M in pentane, 5.45 mL, 9.27 mmol) during 80 min at ⁇ 78° C.
  • CuCN 210 mg, 2.34 mmol
  • THF 5 mL
  • BF 3 etherate 115 ⁇ L, 0.914 mmol
  • thioglycoside A-VI (228 mg, 0.292 mmol) and glycosyl acceptor B-II (129 mg, 0.225 mmol) in dry CH 2 Cl 2 (8 mL) were added via syringe to activated 3 ⁇ molecular sieves (2 g).
  • a suspension of DMTST (177 mg, 0.685 mmol) and activated 3 ⁇ molecular sieves (1 g) in CH 2 Cl 2 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH 2 Cl 2 (2 mL). The reaction was stopped after 48 h and work-up and purification according to general procedure C afforded B-III (253 mg, 87%) as a colorless foam.
  • B-III (100 mg, 77.7 ⁇ mol) was hydrogenated with Pd(OH) 2 /C (52 mg, 10% Pd) in dioxane/H 2 O (4:1, 3.75 mL) according to general procedure D. After 24 h the mixture was filtered through celite and hydrogenated with fresh Pd(OH) 2 /C (50 mg) for another 48 h. The reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (194 ⁇ mol in 190 ⁇ l MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (22 ⁇ L). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford B-IV (40.5 mg, 72%) as a colorless solid.
  • thioglycoside A-VI (218 mg, 0.279 mmol) and glycosyl acceptor C-II (126 mg, 0.215 mmol) in dry CH 2 Cl 2 (8 mL) were added via syringe to activated 3 ⁇ molecular sieves (2 g).
  • a suspension of DMTST (166 mg, 0.644 mmol) and activated 3 ⁇ molecular sieves (1 g) in CH 2 Cl 2 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4.5 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH 2 Cl 2 (2 mL). The reaction was stopped after 65.5 h and work-up and purification according to general procedure C afforded C-III (224 mg, 80%) as a colorless foam.
  • A-IV (106 mg, 0.189 mmol) was dissolved in CH 2 Cl 2 (5 mL) and Grubbs cat. 2 nd gen. (16.0 mg 18.8 ⁇ mol) and methyl acrylate (171 ⁇ L, 1.90 mmol) were added. The reaction was heated under reflux for 9 d. After 1 d, 2 d and 7 d additional Grubbs cat. 2 nd gen. (each 16.0 mg, 18.8 ⁇ mol) and methyl acrylate (each 171 ⁇ L, 1.90 mmol) were added.
  • thioglycoside A-VI 47.9 mg, 61.3 ⁇ mol
  • glycosyl acceptor D-I 29.1 mg, 47.0 ⁇ mol
  • a suspension of DMTST 37.6 mg, 146 ⁇ mol
  • activated 3 ⁇ molecular sieves 250 mg
  • CH 2 Cl 2 2 mL
  • D-III (46.0 mg, 34.4 ⁇ mol) was hydrogenated with Pd(OH) 2 /C (25 mg, 10% Pd) in dioxane/H 2 O (4:1, 3.75 mL) according to general procedure D. After 42 h the mixture was filtered through celite and hydrogenated with fresh Pd(OH) 2 /C (27 mg) for additional 24 h. The reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (3 mL) and sodium methoxide (51.6 ⁇ mol in 55 ⁇ l MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (6 ⁇ L). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford D-III (19.2 mg, 73%) as a colorless solid.
  • rac-E-VI (135 mg, 0.287 mmol) was suspended in MeOH (5 mL). Et 3 N (1 mL) was added and the reaction stirred for 1 h. The solvents were evaporated in vacuo and the residue was purified by MPLC on silica (toluene/ethyl acetate, 6:0 to 6:1) affording rac-E-VII (63.2 mg, 80%) as a white solid.
  • Second compound (5 mg) was mixed with mPEG-nitrophenylcarbonate (5K) 75 mg, triethylamine 5 ul in DMF (2 mL). The resulting mixture was stirred at rt for 3 h. The solvent was removed at reduced pressure. The residue was purified on C-18 to afford 40 mg product.
  • Second compound (20 mg) from Example 11 was mixed with 200 mg 4-arm PEG glutamidylsuccinate, triethylamine 5 ul and DMF 2 mL. The resulting mixture was stirred at it for 2 hr. After removing the solvent, the residue was purified on HPLC to afford the product.
  • E-selectin Protocol The inhibition assay to screen glycomimetic antagonists of E-selectin is a competitive binding assay, which allows the determination of IC 50 values. Briefly, E-selectin/Ig chimera is immobilized by incubation at 37° C. in 96 well microtiter plates for 2 hours. To reduce nonspecific binding, bovine serum albumin is added to each well and incubated at room temperature for 2 hours. The plate is washed and serial dilutions of the test compounds are added to the wells in the presence of conjugates of biotinylated, sLe a polyacrylamide with streptavidin/horseradishperoxidase and incubated for 2 hours at room temperature.
  • the peroxidase substrate 3,3 1 ,5,5 1 tetramethylbenzidin (TMB) is added. After 3 minutes, the enzyme reaction is stopped by the addition of H 3 PO 4 and the absorbance of light at a wavelength of 450 nm is determined. The concentration of test compound required to inhibit binding by 50% is determined and reported as the IC 50 value for each glycomimetic E-selectin antagonist. In addition to reporting the absolute IC 50 value as measured above, relative IC 50 values are determined by a ratio of the IC 50 measured for the test compound to that of a glycomimetic internal control (reference) for each assay. The results from the testing in this assay of several of the compounds disclosed herein are shown below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Compounds and methods are provided for obtaining oligosaccharide mimics. More specifically, compounds and methods are described wherein oligosaccharide mimics are obtained by incorporating or substituting in a cyclohexane derivative.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 11/973,891 filed Oct. 9, 2007, now allowed; which application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 60/851,467 filed Oct. 12, 2006; which applications are incorporated herein by reference in their entirety.
    • BACKGROUND
  • 1. Technical Field
  • The present invention relates generally to compounds and methods for obtaining oligosaccharide mimics, and more particularly for obtaining oligosaccharide mimics by incorporating or substituting in a cyclohexane derivative.
  • 2. Description of the Related Art
  • Naturally occurring monosaccharides and oligosaccharides play a role, or are capable of playing a role, in a variety of biological processes. In certain cases, non-naturally occurring monosaccharides and oligosaccharides may serve to replace or even improve upon their naturally occurring counterparts. Monosaccharides and particularly oligosaccharides may be difficult, and thus costly, to produce. Even where the degree of difficulty to produce is not particularly elevated, the production of monosaccharides and oligosaccharides may still nevertheless be costly. This problem is multiplied where a costly monosaccharide or oligosaccharide needs to be mass produced. While mimics of monosaccharides and oligosaccharides (“glycomimetics”) may improve upon their biological properties, the cost of producing the mimics may not be significantly reduced relative to that which they mimic.
  • Accordingly, there is a need in the art for reducing the production cost or complexity of glycomimetics. The present invention fulfills these needs and further provides other related advantages.
    • BRIEF SUMMARY
  • Briefly stated, the invention provides compounds and methods for obtaining oligosaccharide mimics. In one aspect of the present invention, a method is provided for preparing an oligosaccharide mimic comprising incorporating at least one cyclohexane derivative into an oligosaccharide or glycomimetic compound, wherein the cyclohexane derivative has the formula:
  • Figure US20110257380A1-20111020-C00001
  • wherein,
      • R1═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
      • R2═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2. Also included are products prepared by the method.
  • In another aspect of the present invention, a method is provided for substituting a monosaccharide mimic for at least one hexose or hexosamine in an oligosaccharide compound or glycomimetic compound or in an oligosaccharide or glycomimetic of an oligosaccharide-containing or glycomimetic-containing compound comprising replacing at least one hexose or hexosamine in an oligosaccharide or glycomimetic compound with a cyclohexane derivative, wherein the cyclohexane derivative has the formula:
  • Figure US20110257380A1-20111020-C00002
  • wherein,
      • R1═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
      • R2═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2. Also included are products prepared by the method.
  • In another aspect, the present invention provides an oligosaccharide or glycomimetic compound that contains at least one cyclohexane derivative, wherein the cyclohexane derivative has the formula:
  • Figure US20110257380A1-20111020-C00003
  • wherein,
      • R1═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
      • R2═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2.
  • In another aspect, the present invention provides a compound comprising:
  • Figure US20110257380A1-20111020-C00004
      • R1═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
      • R2═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
      • R3=−OH,
  • Figure US20110257380A1-20111020-C00005
      •  —O—C(═O)—X, —NH2, —NH—C(═O)—NHX, or —NH—C(═O)—X where n=0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl,
  • Figure US20110257380A1-20111020-C00006
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
      • R4=
  • Figure US20110257380A1-20111020-C00007
      •  6′ sulfated GlcNAc, 6′ carboxylated GlcNAc, 6′ sulfated GalNAc, 6′ sulfated galactose, 6′ carboxylated galactose,
  • Figure US20110257380A1-20111020-C00008
      •  where Q is H or a physiologically acceptable salt or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or C1-C14 aryl; or
  • Figure US20110257380A1-20111020-C00009
      •  where R10 is one of
  • Figure US20110257380A1-20111020-C00010
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n=1-4, Z and Y═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and
      • R5═H, D-mannose, L-galactose, D-arabinose, L-fucose, polyols,
  • Figure US20110257380A1-20111020-C00011
      •  where X═CF3, cyclopropyl or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10,
        • or
  • Figure US20110257380A1-20111020-C00012
        •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl,
  • Figure US20110257380A1-20111020-C00013
        •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
  • The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol. As used herein, “another of the compound” refers to either a second compound identical to the first compound, or a second compound that is encompassed by the disclosure herein but not identical to the first compound.
  • In another aspect, the present invention provides a compound consisting of:
  • Figure US20110257380A1-20111020-C00014
      • R1═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
      • R2═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
      • R3=—OH,
  • Figure US20110257380A1-20111020-C00015
      •  —O—C(═O)—X, —NH2, —NH—C(═O)—NHX, or —NH—C(═O)—X where n=0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl,
  • Figure US20110257380A1-20111020-C00016
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
      • R4=
  • Figure US20110257380A1-20111020-C00017
      •  6′ sulfated GlcNAc, 6′ carboxylated GlcNAc, 6′ sulfated GalNAc, 6′ sulfated galactose, 6′ carboxylated galactose,
  • Figure US20110257380A1-20111020-C00018
      •  where Q is H or a physiologically acceptable salt or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8, alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or C1-C14 aryl; or
  • Figure US20110257380A1-20111020-C00019
      •  where R10 is one of
  • Figure US20110257380A1-20111020-C00020
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n=1-4, Z and Y═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and
      • R5═H, D-mannose, L-galactose, D-arabinose, L-fucose, polyols,
  • Figure US20110257380A1-20111020-C00021
      •  where X═CF3, cyclopropyl or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10,
        • or
  • Figure US20110257380A1-20111020-C00022
        •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl,
  • Figure US20110257380A1-20111020-C00023
        •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
  • The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00024
  • where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00025
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00026
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00027
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00028
  • where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00029
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00030
  • where Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00031
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00032
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00033
  • where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00034
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00035
  • where Q is H or a physiologically acceptable salt, and Me is methyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00036
  • where Me is methyl, Et is ethyl, and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00037
  • where Me is methyl and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00038
  • where Me is methyl, Et is ethyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00039
  • where Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • These and other aspects of the present invention will become apparent upon reference to the following detailed description and attached drawings. All references disclosed herein are hereby incorporated by reference in their entirety as if each was incorporated individually.
    • BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS
  • FIG. 1 is a diagram illustrating the synthesis of GlcNAc mimics from tetrahydrophthalic anhydride.
  • FIG. 2 is a diagram illustrating the synthesis of GlcNAc mimics from cyclohexenon.
  • FIG. 3 is a diagram illustrating the synthesis of mimics.
  • FIG. 4 is a diagram illustrating the synthesis of mimics.
  • FIG. 5 is a diagram illustrating the synthesis of mimics.
  • FIG. 6 is a diagram illustrating the synthesis of mimics.
  • FIG. 7 is a diagram illustrating the synthesis of mimics.
  • FIG. 8 is a diagram illustrating the synthesis of mimics.
  • FIG. 9 is a diagram illustrating the synthesis of mimics.
  • FIG. 10 is a diagram illustrating the synthesis of a pegylated mimic.
  • FIG. 11 is a diagram illustrating the synthesis of a pegylated tetramer of a mimic.
  • FIG. 12 is a diagram illustrating the synthesis of mimics.
  • FIG. 13 is a diagram illustrating the synthesis of mimics.
    •  DETAILED DESCRIPTION
  • As noted above, the present invention provides compounds and methods for obtaining monosaccharide and oligosaccharide mimics. Such mimics have a variety of uses in vitro and in vivo, including as antagonists of E-selectin.
  • Within the present invention, an oligosaccharide mimic may be prepared by incorporating one or more cyclohexane derivatives into an oligosaccharide or glycomimetic compound. An oligosaccharide refers to two or more monosaccharides covalently joined. Oligosaccharides are polymers containing monosaccharide units, typically with 2 to about 100 monosaccharides and any integer in-between. Each monosaccharide of an oligosaccharide is independently selected; although two or more monosaccharides may be identical.
  • The cyclohexane derivative of the methods of the present invention has the formula:
  • Figure US20110257380A1-20111020-C00040
  • R1 may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH. R2 may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H. The cyclohexane derivative is attached to the oligosaccharide or glycomimetic compound at least at one of the OH, the R1 or the R2. In embodiments, attachment is at least at one of the OH or the R2. Other options for attachment include at both of the OH, e.g., one monosaccharide or monosaccharide mimic attached at one of the OH and another monosaccharide or monosaccharide mimic attached at the other OH.
  • Such a cyclohexane derivative may also be used in a method for substituting a monosaccharide mimic (a cyclohexane derivative) for at least one hexose or hexosamine. The hexose or hexosamine may be in an oligosaccharide or glycomimetic compound or in an oligosaccharide or glycomimetic possessed by an oligosaccharide-containing or glycomimetic-containing compound. Such a substitution is accomplished by replacing one or more hexose or hexosamine in an oligosaccharide or glycomimetic compound with a cyclohexane derivative. If it is more than one, then each is independently selected. Examples of oligosaccharide-containing compounds include glycoproteins, glycopeptides, glycolipids and glyconucleic acids.
  • As used herein, a “C1-C8 alkanyl” refers to an alkane substituent with one to eight carbon atoms and may be straight chain, branched or cyclic (cycloalkanyl). Examples are methyl, ethyl, propyl, isopropyl, butyl and t-butyl. A “halogenated C1-C8 alkanyl” refers to a “C1-C8 alkanyl” possessing at least one halogen. Where there is more than one halogen present, the halogens present may be the same or different or both (if at least three present). A “C1-C8 alkenyl” refers to an alkene substituent with one to eight carbon atoms, at least one carbon-carbon double bond, and may be straight chain, branched or cyclic (cycloalkenyl). Examples are similar to “C1-C8 alkanyl” examples except possessing at least one carbon-carbon double bond. A “C1-C8 alkynyl” refers to an alkyne substituent with one to eight carbon atoms, at least one carbon-carbon triple bond, and may be straight chain, branched or cyclic (cycloalkynyl). Examples are similar to “C1-C8 alkanyl” examples except possessing at least one carbon-carbon triple bond. An “alkoxy” refers to an oxygen substituent possessing a “C1-C8 alkanyl,” “C1-C8 alkenyl” or “C1-C8 alkynyl.” This is —O-alkyl; for example methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and the like; and alkenyl or alkynyl variations thereof (except for methoxy). It further refers to the group O-alkyl-W-alkyl where W is O or N; for example —O—(CH2)n—W—(CH2)m where n and m are independently 1-10. An “aryl” refers to an aromatic substituent with one to fourteen carbon atoms in one or multiple rings which may be separated by a bond or fused. A “heteroaryl” is similar to an “aryl” except the aromatic substituent possesses at least one heteroatom (such as N, O or S) in place of a ring carbon. Examples of aryls and heteroaryls include phenyl, naphthyl, pyridinyl, pyrimidinyl, triazolo, furanyl, oxazolyl, thiophenyl, quinolinyl and diphenyl. As used herein, the term “independently selected” refers to the selection of identical or different substituents. “Me” and “Et” represent methyl and ethyl, respectively. “Bz” represents benzoyl. “Ar” represents aryl. Examples of physiologically acceptable salts include Na, K, Li, Mg and Ca. Monosaccharide substituents recited herein (e.g., D-mannose, L-galactose, D-arabinose and L-fucose) may be in the furanose, pyranose or open form.
  • A linker arm may be desirable for attachment, for example, to a monosaccharide, a monosaccharide mimic or something else such as an amino acid, nucleic acid or lipid. A linker may include a spacer group, such as —(CH2)n— or —O(CH2)n— where n is generally about 1-20 (all number ranges disclosed herein include any whole integer range therein). An example of a linker is —NH2, e.g., —CH2—NH2 when it includes a short spacer group.
  • Embodiments of linkers include the following:
  • Figure US20110257380A1-20111020-C00041
  • Other linkers with or without a spacer group (e.g., CONH(CH2)2NH2, COOMe, or polyethylene glycol or derivative) will be familiar to those in the art or in possession of the present disclosure.
  • Alternatively, or in combination with a linker arm, a cyclohexane derivative may be attached at one or both OH.
  • The methods of the present invention provide for a variety of compounds. For example, in one embodiment is provided an oligosaccharide or glycomimetic compound that contains at least one cyclohexane derivative, wherein the cyclohexane derivative has the formula:
  • Figure US20110257380A1-20111020-C00042
  • wherein,
  • R1 is defined as above;
  • R2 is defined as above; and
  • the cyclohexane derivative is at least attached to the oligosaccharide or glycomimetic compound at an OH, R1 or R2.
  • In another embodiment is provided a compound comprising:
  • Figure US20110257380A1-20111020-C00043
      • R1 of the formula may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
      • R2 of the formula may be H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
      • R3 of the formula may be —OH,
  • Figure US20110257380A1-20111020-C00044
      •  —O—C(═O)—X, —NH2, —NH—C(═O)—NHX, or —NH—C(═O)—X where n=0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl,
  • Figure US20110257380A1-20111020-C00045
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
      • R4 of the formula may be
  • Figure US20110257380A1-20111020-C00046
      •  6′ sulfated GlcNAc, 6′ carboxylated GlcNAc, 6′ sulfated GalNAc, 6′ sulfated galactose, 6′ carboxylated galactose,
  • Figure US20110257380A1-20111020-C00047
      •  where Q is H or a physiologically acceptable salt or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or C1-C14 aryl; or
  • Figure US20110257380A1-20111020-C00048
      •  where R10 is one of
  • Figure US20110257380A1-20111020-C00049
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n=1-4, Z and Y═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and
      • R5 of the formula may be H, D-mannose, L-galactose, D-arabinose, polyols, L-fucose,
  • Figure US20110257380A1-20111020-C00050
      •  where X═CF3, cyclopropyl or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10,
        • or
  • Figure US20110257380A1-20111020-C00051
        •  or where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl,
  • Figure US20110257380A1-20111020-C00052
        •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
  • In another embodiment is provided a compound consisting of:
  • Figure US20110257380A1-20111020-C00053
      • R1 is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
      • R2 is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; O(═O)X, OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
      • R3 is —OH,
  • Figure US20110257380A1-20111020-C00054
      •  —O—C(═O)—X, —NH2, —NH—C(═O)—NHX, or —NH—C(═O)—X where n=0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl,
  • Figure US20110257380A1-20111020-C00055
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C5 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
      • R4 is
  • Figure US20110257380A1-20111020-C00056
      •  6′ sulfated GlcNAc, 6′ carboxylated GlcNAc, 6′ sulfated GalNAc, 6′ sulfated galactose, 6′ carboxylated galactose,
  • Figure US20110257380A1-20111020-C00057
      •  where Q is H or a physiologically acceptable salt or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)n-aryl or (CH2)n-heteroaryl where n is 1-10, and where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or C1-C14 aryl; or
  • Figure US20110257380A1-20111020-C00058
      •  where R10 is one of
  • Figure US20110257380A1-20111020-C00059
    Figure US20110257380A1-20111020-C00060
      •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n=1-4, Z and Y═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and
      • R5 is H, D-mannose, L-galactose, D-arabinose, L-fucose, polyols,
  • Figure US20110257380A1-20111020-C00061
      •  where X═CF3, cyclopropyl or C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10,
        • or
  • Figure US20110257380A1-20111020-C00062
        •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where R11 is aryl, heteroaryl,
  • Figure US20110257380A1-20111020-C00063
        •  where Q is H or a physiologically acceptable salt, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any one of the above ring compounds may be substituted with one to three independently selected of Cl, F, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl or OY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl or C1-C8 alkynyl.
  • In another embodiment is provided a compound having the formula:
  • Figure US20110257380A1-20111020-C00064
  • where Q is H or a physiologically acceptable salt, and Me is methyl.
  • In another embodiment is provided a compound having the formula:
  • Figure US20110257380A1-20111020-C00065
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • In another embodiment is provided a compound having the formula:
  • Figure US20110257380A1-20111020-C00066
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • In another embodiment is provided a compound having the formula:
  • Figure US20110257380A1-20111020-C00067
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • In another embodiment is provided a compound having the formula:
  • Figure US20110257380A1-20111020-C00068
  • where Q is H or a physiologically acceptable salt, and Me is methyl.
  • In another embodiment is provided a compound having the formula:
  • Figure US20110257380A1-20111020-C00069
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • In another embodiment is provided a compound having the formula:
  • Figure US20110257380A1-20111020-C00070
  • where Me is methyl.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00071
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00072
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00073
  • where Q is H or a physiologically acceptable salt, and Me is methyl.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00074
  • where Q is H or a physiologically acceptable salt, Me is methyl and Bz is benzoyl.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00075
  • where Q is H or a physiologically acceptable salt, and Me is methyl.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00076
  • where Me is methyl, Et is ethyl, and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00077
  • where Me is methyl and Bz in benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00078
  • where Me is methyl, Et is ethyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • In an embodiment, the present invention provides a compound having the formula:
  • Figure US20110257380A1-20111020-C00079
  • where Me is methyl and Bz is benzoyl. The compound may include a polyethylene glycol attached thereto. Alternatively, multimers may be formed whereby the compound is attached to another of the compound by polyethylene glycol.
  • For the compounds described herein, a free acid substituent, e.g., CO2H and (O═)S(═O)OH, encompasses a sodium salt of the acid, e.g., COONa and (O═)S(═O)ONa, and vice versa. Furthermore, a sodium salt of the acid is merely representative and any physiologically acceptable acid salt (e.g., Li, K, Mg and Ca) is encompassed. In addition, for the compounds described herein, a free acid substituent (or salt thereof) may be modified as an ester (e.g., alkanyl ester) or as an amide or amide-like (e.g., CONHOH).
  • For the compounds described herein (both generically and specifically), a polyethylene glycol (PEG), including derivatives thereof, may be attached to a compound. Alternatively, multimers of the same compound or different compounds of the compounds described herein (i.e., two or more compounds joined to one another) may be formed using PEG. Examples of particular compounds amenable to the attachment of a PEG or to the formation of a multimer including PEG, are disclosed above as embodiments of the present invention. Procedures for preparing a pegylated compound or pegylated multimers will be familiar to those in the art or in possession of the present disclosure. Examples are depicted in FIG. 10 (a pegylated compound) and FIG. 11 (a pegylated tetramer).
  • The following Examples are offered by way of illustration and not by way of limitation.
    • EXAMPLES Example 1 Synthesis of GlcNAc Mimic From Tetrahydrophthalic Anhydride (FIG. 1) Synthesis of Intermediate I:
  • Amberlyste 15 (50.0 g) was placed in a flask and dried in high vacuo for 1 h. Methanol (1 l) was added, followed by cis-1,2,3,6-tetrahydrophthalic anhydride (50.0 g, 328 mmol) and trimethylorthoformate (100 ml, 914 mmol). The reaction mixture was then vigorously stirred. After 5 days, additional trimethylorthoformate (50 ml, 457 mmol) was added. The reaction was stopped after 9 days (TLC-control:petroleum ether/Et2O, 1:2), filtered over celite and washed with methanol. The solvent was removed in vacuo (20 mbar). The brown residue was transferred with CH2Cl2 (150 ml) into a separation funnel and washed with satd. NaHCO3 solution and brine (each 150 ml). The aqueous layers were extracted 3 times with CH2Cl2 (3×150 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (20 mbar) to afford diester I as a brownish oil (57.5 g, 88%).
    • Synthesis of Intermediate II:
  • To a stirred suspension of diester I (2.00 g, 10.1 mmol) in pH 7.00 phosphate buffer solution (103 ml, 0.07 M), PLE (8.00 mg, 216 units) was added. The pH was kept at 7 by adding continuously NaOH solution (1.0 M) via syringe pump. The reaction was stirred at 20° C. until one equivalent of NaOH (10 ml) was used (56.5 h, TLC-control:petroleum ether/Et2O, 1:2). The reaction mixture was transferred into a separation funnel with ethyl acetate (100 ml). The layers were separated and the organic layer was extracted twice with pH 7.00 phosphate buffer solution (2×60 ml). The combined aqueous layers were acidified to pH 2 with 1 M HCl solution and extracted four times with ethyl acetate (4×150 ml). To separate the layers NaCl was added. The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to afford the monoester II as a yellowish oil (1.67 g, 90%). 96.0% ee. (GC), 96.4% ee. (rot.), [α]D 21+15.23° (c=0.195, EtOH), (Lit.+15.8° (c=0.2, EtOH), [Angew. Chem. Int. Ed. Engl., 1984, 23, 142]).
    • Synthesis of Intermediate III:
  • A solution of monoester II (0.992 g, 5.38 mmol) in dry CH2Cl2 (18 ml) was treated with (COCl)2 (0.7 ml, 8.15 mmol) and DMF (14 μl), stirred for 3 h at r.t. and evaporated (rotavapor purged with argon). A solution of the residue in dry THF (20 ml) was added dropwise over a period of 20 minutes to a boiling suspension of 2-mercaptopyridine-1-oxide sodium salt (974.8 mg, 6.49 mmol), t-BuSH (3.1 ml, 27.5 mmol), and 4-DMAP (26.3 mg, 0.216 mmol) in dry THF (50 ml). The solution was stirred at reflux for 3 h (TLC-control:petroleum ether/Et2O, 10:1). The reaction mixture was then cooled down to r.t. (room temperature) and transferred into a separation funnel with ethyl acetate (50 ml) and washed with water (100 ml). The aqueous layer was extracted twice with ethyl acetate (2×100 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (200 mbar). The crude product was purified by column chromatography (petroleum ether/Et2O, 30:1 to 15:1) to afford methylester III as a yellowish oil (584.9 mg, 83%). [α]D 21+78.23° (c=1.010, CHCl3).
    • Synthesis of Intermediate IV:
  • To a stirred suspension of methylester III (5.19 g, 37.0 mmol) in pH 7.00 phosphate buffer solution (520 ml, 0.07 M), PLE (51.2 mg, 1382 units) was added. The pH was kept at 7 by adding NaOH solution (1.0 M) via syringe pump. The reaction was stirred at r.t. until one equivalent of NaOH (37 ml) was used (11 h, TLC-control:petroleum ether/Et2O, 1:1). The reaction mixture was transferred into a separation funnel and washed twice with ethyl acetate (2×300 ml). The layers were separated and the organic layers were extracted twice with pH 7.00 phosphate buffer solution (2×300 ml). The combined aqueous layers were acidified to pH 2 with aqueous HCl (30 ml, 4 M) and extracted three times with ethyl acetate (3×400 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (100 mbar). The crude product was filtered through a short plug of silica affording acid IV as a pale yellowish oil (3.92 g, 84%). 96.3% ee. (GC), 94.3% ee. (rot.), [α]D 21+89.12° (c=6.730, MeOH), (Lit.+94.5° (c=7, MeOH), [Acta Chem. Scand., 1970, 24, 2693]).
    • Synthesis of Intermediate V:
  • Acid IV (8.30 g, 65.7 mmol) was placed in a flask purged with argon and suspended in water (180 ml). The reaction mixture was cooled down to 0° C. and NaHCO3 (16.6 g, 197 mmol) was added, followed by a solution of KI (65.4 g, 394 mmol) and iodine (17.5 g, 68.9 mmol) in water (150 ml). The reaction was stirred at r.t. for 24 h and then extracted three times with CH2Cl2 (3×60 ml). The combined organic layers were washed with a solution of Na2S2O3 (50 g) in water (250 ml). The aqueous layer was extracted twice with CH2Cl2 (2×60 ml). The combined organic layers were protected from light, dried over Na2SO4, filtered and concentrated in vacuo (20 mbar) and quickly in high vacuo to afford iodolactone V as an off-white solid (15.79 g, 95%). [α]D 21+35.96° (c=0.565, CHCl3).
    • Synthesis of Intermediate VI:
  • Iodolactone V (15.73 g, 62.2 mmol) was dissolved in dry THF (340 ml). Then DBU (14 ml, 93.3 mmol) was added and the mixture was refluxed for 20 h (TLC-control:petroleum ether/Et2O, 1:1). The reaction mixture was cooled down to r.t., transferred with Et2O (200 ml) into a separation funnel and extracted with aqueous HCl (400 ml, 0.5 M) and brine (400 ml). The aqueous layers were extracted three times with Et2O (3×200 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (350 mbar). The crude product was purified by column chromatography (petroleum ether/CH2Cl2/Et2O, 20:5:1 to 8:5:1) to afford lactone VI as a yellowish oil (7.28 g, 94%). [α]D 21+187.31° (c=1.080, CHCl3).
    • Synthesis of Intermediate VII:
  • NaHCO3 (4.36 g, 51.8 mmol) was dried in high vacuum for 2 h. Then, freshly distilled methanol (268 ml) was added followed by lactone VI (6.38 g, 51.4 mmol). The reaction mixture was then stirred under argon for 12 h (TLC-control:petroleum ether/Et2O, 1:1). The solvent was evaporated and the residue transferred into a separation funnel with CH2Cl2 (60 ml) and extracted with water (60 ml) and brine (60 ml). The aqueous layers were extracted twice with CH2Cl2 (2×60 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (50 mbar) to obtain the alcohol as a yellowish oil (7.77 g, 96%). To a solution of the alcohol in dry CH2Cl2 (150 ml), tert-butyldimethylsilyl chloride (14.93 g, 99 mmol) was added in small portions, followed by DBU (18.4 ml, 123.4 mmol). The reaction was stirred at r.t for 12 h (TLC-control:petroleum ether/Et2O, 20:1) and then quenched with methanol (20 ml). The reaction mixture was transferred into a separation funnel with CH2Cl2 (100 ml), washed with satd. NaHCO3 solution (100 ml) and brine (100 ml). The aqueous layers were extracted twice with CH2Cl2 (2×100 ml). The combined organic layers were dried over Na2SO4, filtered and evaporated (200 mbar). The crude product was purified by column chromatography (petroleum ether/Et2O, 40:1 to 20:1) to afford silylether VII as a colourless oil (13.96 g, quantitative yield). [α]D 21+1.97° (c=1.045, CHCl3).
    • Synthesis of Intermediate VIII:
  • A solution of silylether VII (1.21 g, 4.47 mmol) in CH2Cl2 (36 ml) was cooled to 10° C., then m-CPBA (1.92 g, 11.1 mmol) was added in one portion. The reaction mixture was stirred at 10° C. for 15 h. Over a period of 2 hours the temperature was raised to r.t and the reaction stopped (TLC-control:petroleum ether/Et2O, 5:1). The mixture was diluted with CH2Cl2 (150 ml) and transferred into a separation funnel. The excess of m-CPBA was destroyed by washing twice with satd. Na2S2O3 solution (2×150 ml). The organic layer was successively washed with satd. NaHCO3 solution (150 ml) and brine (150 ml). The aqueous layers were extracted twice with CH2Cl2 (2×100 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/Et2O, 12:1 to 10:1) to obtain epoxide VIII as yellowish oil (1.001 g, 78%). [α]D 21-25.60 (c=0.985, CHCl3).
    • Synthesis of Intermediate IX:
  • CuCN (635.4 mg, 7.09 mmol) was dried in high vacuo at 150° C. for 30 minutes, suspended in dry THF (10 ml) and cooled down to −78° C. MeLi (1.6 M in Et2O, 8.90 ml, 14.2 mmol) was slowly added via syringe and the temperature was raised over a period of 30 minutes to −10° C. The mixture was again cooled down to −78° C. followed by the addition of freshly distilled BF3 etherate (360 μl) in THF (2 ml). After stirring for 20 minutes, epoxide VIII (408.0 mg, 1.42 mmol) in THF (10 ml) was added. The reaction was stopped after 5 h stirring at −78° C. (TLC-control:petroleum ether/Et2O, 3:1). The excess of MeLi was quenched with a mixture of methanol (4 ml) and triethylamine (4 ml). The mixture was transferred with Et2O (100 ml) into a separation funnel and extracted with 25% aq. NH3/satd. NH4Cl (1:9) solution. The organic layer was then successively washed with brine (60 ml), 5% acetic acid (60 ml), satd. NaHCO3 solution (60 ml) and brine (60 ml). The aqueous layers were extracted twice with Et2O (2×100 ml). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo (20 mbar). The crude product was purified by column chromatography (petroleum ether/Et2O, 10:1 to 8:1) to afford GlcNAc-mimic IX as a reddish oil (337.0 mg, 78%). [α]D 21−28.34° (c=1.020, CHCl3).
    • Synthesis of Intermediate X:
  • After a mixture of IX (347.5 mg, 1.15 mmol), ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (1.111 g, 2.32 mmol), (Bu)4NBr (1.122 g, 3.48 mmol), 2,6-di-tert-butyl-4-methylpyridine (713.3 mg, 3.47 mmol), and powdered 4 Å molecular sieves (3 g) in CH2Cl2 (12 ml) and DMF (3 ml) was stirred at r.t. under Ar for 4 h, CuBr2 (775.9 mg, 3.47 mmol) was added and the reaction mixture was stirred at r.t. for 20 h (TLC-control: toluene/petroleum ether/EtOAc, 3:3:1). The reaction mixture was filtered over Celite and the filtrate was diluted with CH2Cl2 (20 ml). The organic layer was washed with satd. NaHCO3 solution and brine (each 40 ml) and the aqueous layers were extracted three times with CH2Cl2 (3×40 ml). The combined organic layers were dried with Na2SO4, filtered and co-evaporated with toluene to dryness. The residue was purified by column chromatography (petroleum ether/Et2O, 7:1 to 5:1) to yield compound X as a yellowish oil (631.4 mg, 76%). [α]D 21-40.66° (c=0.790, CHCl3).
    • Synthesis of Intermediate XI:
  • To a solution of disaccharide mimic X (139.5 mg, 0.194 mmol) in THF (5 ml), TBAF (390 μl, 0.390 mmol) was added. After 26 h additional TBAF (200 μl, 0.200 mmol) was added, and the solution was continued stirring. The reaction was stopped after 50 h and concentrated in vacuo (TLC-control:petroleum ether/ethyl acetate, 5:1). The crude product was purified by column chromatography (petroleum ether/ethyl acetate, 3:1) to afford the unprotected disaccharide mimic XI as a white solid (95.7 mg, 81%). [α]D 21−43.03° (c=1.090, CHCl3).
    • Synthesis of Intermediate XII:
  • Dry CH2Cl2 (16 ml) was added to a mixture of the thioglycoside (562.3 mg, 0.719 mmol), glycosyl acceptor XI (335.6 mg, 0.555 mmol) and activated 4 Å molecular sieves (4 g) under argon atmosphere. A suspension of DMTST (440.6 mg, 1.706 mmol) and activated 4 Å molecular sieves (2 g) in CH2Cl2 (8 ml) was prepared in a second flask. Both suspensions were stirred at room temperature for 4 h, before adding the DMTST suspension via syringe to the other suspension with some additional CH2Cl2 (1 ml). The reaction was stopped after 63 h (TLC-control:petroleum ether/Et2O, 1:1), and filtered through celite, washing with CH2Cl2. The filtrate was successively washed with satd. solution of NaHCO3 (40 ml) and water (100 ml). The aqueous layers were three times extracted with DCM (3×60 ml). The combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by repeated column chromatography (petroleum ether/Et2O, 1:1) to afford tetrasaccharide XII as a white foam (484.9 mg, 66%). [α]D 21−52.80 (c=1.050, CHCl3).
    • Synthesis of Product XIII:
  • A mixture of XII (132.5 mg, 0.100 mmol), Pd(OH)2/C (50 mg), dioxane (3 ml) and water (0.75 ml) was hydrogenated in a Parr-shaker under 4 bar at r.t. After 20 h the mixture was filtered through Celite and set up with new Pd(OH)2/C (50 mg) for another 26 h, after which TLC control indicated completion of the reaction. The reaction mixture was filtered over Celite and evaporated to dryness. The residue was redissolved in methanol (4 ml) and sodium methanolate (0.150 mmol in 160 μl MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (17 μl). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford compound XIII as a white solid (57.1 mg, 76%). [α]D 21−85.02° (c=0.570, MeOH).
    • Example 2 Synthesis of GlcNAc Mimics From Cyclohexenon (FIG. 2) Synthesis of Intermediate XIV:
  • 2-Cyclohexenone (9.8 ml, 101 mmol) was dissolved in CH2Cl2 (250 ml) in a light protected flask, then the solution was cooled to 0° C. Bromine (5.4 ml, 105 mmol) in CH2Cl2 (100 ml) was added via dropping funnel over 35 min. The clear yellow solution was stirred at 0° C. for 2.5 h, then Et3N (23.1 ml, 166 mmol) in CH2Cl2 (20 ml) was added portion-wise via dropping funnel, causing a colour change from clear yellow to brown with precipitate. The mixture was stirred at room temperature for 2 h, then stopped. The reaction mixture was diluted with CH2Cl2 (50 ml) and washed twice with HCl 3% (2×50 ml). The aqueous layers were extracted with CH2Cl2 (2×25 ml) and the combined organic layers were washed with a mixture of brine (80 ml) and water (100 ml). The layers were separated and the aqueous layer was extracted with CH2Cl2 (2×50 ml). The combined organic layers were concentrated in vacuo to afford a brown residue still dissolved in a few ml of CH2Cl2, and was then treated with activated charcoal and filtered through celite. The clear green mixture was concentrated to dryness. Recrystallization from hexane/EtOAc (100 ml:few drops) gave offwhite crystals. The crystals were dried in a desiccator for 12 h affording bromide XIV (11.0 g, 62.8 mmol, 62%). 1H-NMR (CDCl3, 500.1 MHz): δ=2.07 (m, 2H, H-5), 2.45 (m, 2H, H-4), 2.63 (m, 2H, H-6), 7.42 (t, 3J=4.4 Hz, 1H, H-3).
    • Synthesis of Intermediate XV:
  • (S)-α,α-diphenylprolinol (290 mg, 1.14 mmol) was dissolved in THF (20 ml) in a flame dried, light protected flask, then under stirring B(OMe)3 (153 μl, 1.37 mmol) was added via syringe to the solution. The mixture was stirred for 1 h at room temperature, before BH3.N,N-diethylaniline (2.00 ml, 11.2 mmol) was added and the resulting solution cooled to −10° C. A solution of bromide XIV (2.00 g, 11.4 mmol) in THF (15 ml) was then added over 45 min. The clear yellow mixture was stirred for 3 h at 0° C. After complete conversion of the ketone the reaction was quenched with HCl (1 M, 20 ml). The resulting mixture was diluted with CH2Cl2 (40 ml) and water (50 ml). After separation the organic layer was washed with brine (20 ml) and both aqueous layers were extracted twice with CH2Cl2 (2×25 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. Chromatographic purification of the crude product (petroleum ether/Et2O, 2:1 to 1.5:1) gave XV (1.89 g, 10.7 mmol, 93%) as a colourless oil and with an optical yield of 96% ee determined by optical rotation and derivatisation with (1R)-(−)-MTPA-Cl. [α]D 21+83.0 (c=1.01; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=1.59-1.66 (m, 1H, H-5a), 1.69-1.77 (m, 1H, H-5b), 1.86-1.97 (m, 2H, H-6a, H-6b), 2.00-2.07 (m, 1H, H-4a), 2.09-2.16 (m, 1H, H-4b), 2.26 (m, 1H, OH), 4.20 (m, 1H, H-1), 6.19 (t, 3J=4.0 Hz, 1H, H-3).
    • Synthesis of Intermediate XVI:
  • XV (7.33 g, 41.4 mmol) was dissolved in Et2O (43 ml) in a flame dried flask equipped with a dropping funnel. tert-BuLi (1.7 M in pentane, 133 mmol) was dropwise added at −78° C. over 1 h and 15 min. After complete addition, the clear yellowish mixture was stirred for further 1 h and 30 min at −78° C. and was then warmed up to −20° C. over 3 hrs and 15 min. The reaction was quenched by addition of satd. solution of NaHCO3 (50 ml) and stirred for a further hour at room temperature. The reaction was diluted by addition of water (20 ml) and Et2O (20 ml). The layers were separated and the aqueous layer extracted twice with Et2O (2×30 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo (>200 mbar) to afford a yellow mixture (still presence of solvent) which was purified by column chromatography (petroleum ether/Et2O, 2:1 to 1:1). The product was mostly concentrated in vacuo (>200 mbar), then the rest of the solvent was removed by distillation under argon with vigreux column to afford alcohol XVI (3.39 g, 34.6 mmol, 85%) as a clear brown oil. [α]D 21=+117.7 (c=0.95; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=1.53-1.64 (m, 3H, H-5a, H-6a, OH), 1.68-1.77 (m, 1H, H-5b), 1.87 (m, 1H, H-6b), 1.92-2.06 (m, 2H, H-4a, H-4b), 4.19 (s, 1H, H-1), 5.74 (dd, 3J=2.4, 10.0 Hz, 1H, H-2), 5.82 (m, 1H, H-3).
    • Synthesis of Intermediate XVII:
  • Alcohol XVI (1.51 g, 15.3 mmol) was stirred in CH2Cl2 (35 ml) at room temperature. Trityl chloride (9.54 g, 34.2 mmol) was added to the mixture, then DBU (5.9 ml, 39.5 mmol) was added via syringe. The brown mixture was stirred for 45 h, then stopped. The reaction mixture was diluted with CH2Cl2 (50 ml) and washed with satd. solution of NaHCO3 (50 ml). The layers were separated and the aqueous layer was extracted twice with CH2Cl2 (2×25 ml). The combined organic layers were dried with Na2SO4 and concentrated to dryness. The resulting viscous brown oil was purified by column chromatography (petroleum ether/toluene, 11:1 to 4:1) affording tritylether XVII (3.72 g, 10.9 mmol, 71%) as a yellow solid. [α]D 21=+74.6 (c=1.15; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=1.31-1.41 (m, 3H, H-5a, H-6), 1.68-1.76 (m, 1H, H-5b), 1.80 (m, 1H, H-4a), 1.98 (m, 1H, H-4b), 4.06 (s, 1H, H-1), 5.03 (m, 1H, H-2), 5.61 (m, 1H, H-3), 7.21-7.54 (m, 15H, 3 C6H5); elemental analysis calcd (%) for C25H24O (340.46): C, 88.20; H, 7.10. found: C, 88.01; H, 7.29.
    • Synthesis of Intermediate Anti-XVIII:
  • Tritylether XVII (948 mg, 2.79 mmol) was dissolved under argon atmosphere in CH2Cl2 (30 ml) and NaHCO3 (281 mg, 3.34 mmol) was added. The mixture was cooled to 0° C. and under stirring m-chloroperbenzoic acid (70%, 960 mg, 5.56 mmol) was added. After stirring for 1.5 h the reaction temperature was gradually raised to room temperature and the mixture was stirred for another 3.5 h. The reaction was diluted with CH2Cl2 (50 ml) and transferred to a separation funnel. The excess of m-chloroperbenzoic acid was destroyed by washing with satd. solution of Na2S2O3 (2×150 ml). The organic layer was then successively washed with satd. Na2CO3 solution (150 ml) and brine (150 ml). The aqueous layers were each time extracted with CH2Cl2 (2×50 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/EtOAc, 20:1 to 15:1) affording epoxide anti-XVIII (714 mg, 2.00 mmol, 72%) as colourless solid. [α]D 21=+26.6 (c=0.67; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=1.02-1.11 (m, 1 H, H-5a), 1.15-1.22 (m, 1H, H-6a), 1.37-1.43 (m, 1H, H-5b), 1.53 (m, 1H, H-6b), 1.64-1.71 (m, 1H, H-4a), 1.90 (m, 1H, H-4b), 2.25 (m, 1H, H-2). 2.97 (m, 1H, H-3), 3.86 (m, 1H, H-1), 7.23-7.53 (m, 15H, 3 C6H5); elemental analysis calcd (%) for C25H24O2 (356.46): C, 84.24; H, 6.79. found: C, 83.86; H, 6.85.
    • Synthesis of Intermediate XIX:
  • Copper(I) iodide (499 mg, 2.62 mmol) was dried at high vacuo at 200° C. for 30 minutes, then flushed with argon and suspended in dry diethylether (10 ml). After cooling to −20° C. MeLi (1.6 M in ether, 3.26 ml, 5.22 mmol) was slowly added and the solution was stirred for 15 minutes. A solution of epoxide anti-XVIII (310 mg, 0.870 mmol) in diethylether (7 ml) was added to the cuprate. After stirring for 30 minutes at −20° C. the reaction mixture was slowly brought to room temperature and stirred for one week. The reaction was diluted with tert-butyl methyl ether (10 ml) and quenched at 0° C. with satd. solution of NaHCO3 (10 ml). The reaction mixture was further diluted and extracted with tert-butyl methyl ether and satd. solution of NaHCO3 (each 20 ml). The aqueous layer was extracted twice with tert-butyl methyl ether (2×50 ml). The combined organic layers were dried with Na2SO4 and concentrated. The residue was purified by flash chromatography (petroleum ether/EtOAc/Et3N, 13:1:0.07) to yield XIX (206 mg, 64%) as yellowish resin. [α]D 21=−57.6 (c=0.52; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=0.78 (m, 1H, H-5a), 0.94 (m, 1H, H-4a), 1.00 (d, 3J=6.4 Hz, 3H, CH3), 1.17 (m, 1H, H-3), 1.32 (m, 1H, H-6a), 1.40 (m, 1H, H-5b), 1.46-1.49 (m, 2H, H-4b, H-6b), 2.67 (s, 1H, OH), 2.83 (ddd, 3J=4.1, 8.6, 11.1 Hz, 1H, H-1), 3.32 (t, 3J=9.2 Hz, 1H, H-2), 7.21-7.30, 7.49-7.50 (m, 15H, 3 C6H5); elemental analysis calcd (%) for C26H28O2 (372.51): C, 83.83; H, 7.58. found: C, 83.51; H, 7.56.
    • Synthesis of Intermediate XX:
  • A solution of Br2 (43 μl, 0.837 mmol) in CH2Cl2 (1 ml) was added dropwise at 0° C. to a solution of ethyl 2,3,4-tri-O-benzyl-L-fucothiopyranoside (349 mg, 0.729 mmol) in CH2Cl2 (2 ml). After stirring for 50 min at 0° C., cyclohexene (100 μl) was added and the solution stirred for another 20 min. The mixture was dropwise added to a solution of XIX (208 mg, 0.558 mmol) and Et4NBr (154 mg, 0.733 mmol) in DMF/CH2Cl2 (10 ml, 1:1) which has been stirred with activated 3 Å molecular sieves (850 mg) for 2 h. The mixture was stirred for 14 h at room temperature. The reaction was quenched with pyridine (1 ml) and filtered over celite with addition of CH2Cl2 (20 ml). The solution was washed with brine (40 ml) and the aqueous layer was extracted with CH2Cl2 (3×30 ml). The combined organic phases were dried with Na2SO4, the solvent was removed azeotropic with toluene, and the residue was purified by flash chromatography (petroleum ether/toluene/ethyl acetate/Et3N, 20:5:1:0.26) to afford 254 mg (58%, 0.322 mmol) of XX as colorless foam. [α]D 21=−36.4 (c=0.51; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=0.81 (d, 3J=6.5 Hz, 3H, Fuc H-6), 1.05 (m, 1H, H-6a), 1.18 (d, 3J=7.6 Hz, 3H, CH3), 1.15-1.28 (m, 2H, H-4a, H-5a), 1.34 (m, 1H, H-6b), 1.75 (m, 1H, H-4b), 1.85-1.90 (m, 2H, H-3, H-5b), 2.91 (m, 1H, H-2), 3.52 (m, 1H, Fuc H-4), 3.64 (m, 1H, Fuc H-5), 3.76 (dd, 3J=2.7, 10.1 Hz, 1H, Fuc H-3), 3.81 (m, 1H, H-1), 3.88 (dd, 3J=3.6, 10.1 Hz, 1H, Fuc H-2), 4.54 (m, 1H, CH2Ph), 4.61 (d, 1H, Fuc H-1), 4.61, 4.64, 4.65, 4.77, 4.92 (5 m, 5H, 3 CH2Ph), 7.17-7.34, 7.48-7.50 (m, 30H, 6 C6H5).
    • Synthesis of Intermediate XXI:
  • To a stirred solution of tritylether XX (241 mg, 0.305 mmol) in CH2Cl2 (4 ml), ZnBr2 (208 mg, 0.924 mmol) and triethylsilane (55 μl, 0.344 mmol) was added. The reaction was quenched after 8 h by adding 100 μl water. CH2Cl2 (10 ml) was added and the reaction mixture extracted with satd. solution of NaHCO3 (30 ml). After separation the aqueous layer was extracted twice with DCM (2×20 ml). The combined organic layers were washed with satd. solution of NaHCO3 (50 ml) and the aqueous layer was extracted twice with DCM (2×50 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. Chromatographic purification of the crude product (petroleum ether/toluene/ethyl acetate, 5:5:1) gave 140 mg (84%, 0.256 mmol) of XXI as yellowish solid. [α]D 21=−35.0 (c=0.45; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=0.98 (m, 1H, H-4a), 1.08 (d, 3J=6.4 Hz, 3H, CH3), 1.16 (d, 3J=6.5 Hz, 3H, Fuc H-6), 1.22-1.30 (m, 2H, H-5a, H-6a), 1.51 (m, 1H, H-3), 1.61-1.67 (m, 2H, H-4b, H-5b), 2.00 (m, 1H, H-6b), 2.87 (t, 3J=9.3 Hz, 1H, H-2), 3.37 (m, 1H, H-1), 3.70 (m, 1H, Fuc H-4), 3.97 (dd, 3J=2.7, 10.2 Hz, 1H, Fuc H-3), 4.10-4.14 (m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.70, 4.76, 4.77, 4.86, 4.99 (6 m, 6H, 3 CH2Ph), 5.00 (d, 1H, Fuc H-1), 7.25-7.39 (m, 15H, 3 C6H5); elemental analysis calcd (%) for C34H42O6 (546.69): C, 74.70; H, 7.74. found: C, 74.68; H, 7.80.
    • Synthesis of Intermediate XXII:
  • Dry CH2Cl2 (8 ml) was added to a mixture of the thioglycoside (254 mg, 0.325 mmol), the glycosyl acceptor XXI (137 mg, 0.251 mmol) and activated 4 Å molecular sieves (2 g) under argon atmosphere. A suspension of DMTST (206 mg, 0.798 mmol) and activated 4 Å molecular sieves (1 g) in CH2Cl2 was prepared in a second flask. Both suspensions were stirred at room temperature for 4 h, before adding the DMTST suspension via syringe to the other suspension. The reaction was stopped after 43 h and filtered through celite, washing with CH2Cl2. The filtrate was successively washed with satd. solution of NaHCO3 (20 ml) and water (60 ml). The aqueous layers were each time extracted with DCM (3×30 ml). The combined organic layers were dried with Na2SO4 and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/toluene/ethyl acetate, 7:7:1 to 5:5:1) to afford 187 mg (59%, 0.148 mmol) of XXII as colourless foam. [α]D 21=−51.0 (c=0.51; CHCl3); 1H-NMR (CDCl3, 500.1 MHz): δ=0.45-1.46 (m, 19H, CyCH2, MeCy), 1.04 (d, 3J=6.3 Hz, 3H, CH3), 1.44 (d, 3J=6.4 Hz, 3H, Fuc H-6), 1.86 (m, 1H, MeCy), 3.21 (t, 3J=9.1 Hz, 1H, H-2), 3.48 (m, 1H, H-1), 3.51 (s. 1H, Fuc H-4), 3.82 (dd, 3J=3.3, 9.9 Hz, 1H, Gal H-3), 3.91 (m, 1H, Gal H-5), 4.02 (dd, 3J=3.3, 10.3 Hz, 1H, Fuc H-2), 4.05 (dd, 3J=2.3, 10.3 Hz, 1H, Fuc H-3), 4.12 (dd, 3J=4.6, 7.9 Hz, 1H, Lac H-2), 4.24 (dd, 3J=7.2 Hz, 2J=11.4 Hz, 1H, Gal H-6a), 4.26 (m, 1H, CH2Ph), 4.38 (dd, 3J=5.7 Hz, 2J=11.4 Hz, 1H, Gal H-6b), 4.51 (m, 1H, CH2Ph), 4.54 (d, 3J=8.2 Hz, 1H, Gal H-1), 4.63, 4.67, 4.74, 4.77 (4 m, 4H, 2 CH2Ph), 4.88 (m, 1H, Fuc H-5), 5.05 (m, 1 H, CH2Ph), 5.06 (d, 3J=3.5 Hz, 1H, Fuc H-1), 5.11 (m, 1H, CH2Ph), 5.60 (m, 1H, Gal H-2), 5.84 (m, 1H, Gal H-4), 7.17-7.34, 7.42-7.46, 7.52-7.58, 8.03-8.12 (m, 35 H, 7 C6H5); elemental analysis calcd (%) for C77H84O16 (1265.48): C, 73.08; H, 6.69. found: C, 73.16; H, 6.76.
    • Synthesis of Product XXIII:
  • Pd/C (50 mg, 10% Pd) was suspended under argon atmosphere in ethanol (3 ml) with a catalytic amount of acetic acid. Compound XXII (101 mg, 79.8 μmol) was added and the resulting mixture was hydrogenated under 70 psi at room temperature. After 1 day another 50 mg of Pd/C were added and hydrogenation was continued for another 5 days. The reaction was quenched with CH2Cl2 and filtered on celite, washing with methanol. The filtrate was concentrated under vacuum, redissolved in methanol/water (3:1, 4 ml) and lithium hydroxide (100 mg, 4.18 mmol) was added. After 2 days stirring the mixture was neutralized with Dowex 50×8 (H+), filtered through a Dowex 50 ion exchanger column (Na+ form) and concentrated in vacuo. The residue was purified by column chromatography (CH2Cl2/methanol/water, 5:1:0.1 to 5:2.5:0.25), followed by Sephadex G15 column and lyophilization from dioxane to give 36.5 mg (74%, 59.4 μmol) of XXIII as colourless foam. [α]D 21=−84.8 (c=0.32; MeOH); 1H-NMR (MeOD, 500.1 MHz): δ=0.87-1.00 (m, 2H, CyCH2, MeCy), 1.04-1.38 (m, 6H, CyCH2, MeCy), 1.13 (d, 3J=6.3 Hz, 3H, CH3), 1.20 (d, 3J=6.5 Hz, 3H, Fuc H-6), 1.55-1.74 (m, 10H, CyCH2, MeCy), 1.92 (m, 1H), 2.13 (m, 1H, MeCy), 3.20 (t, 3J=9.3 Hz, 1H, H-2), 3.24 (dd, 3J=2.8, 9.3 Hz, 1H, Gal H-3), 3.42 (m, 1H, Gal H-5), 3.62-3.68 (m, 3H, Gal H-2, Gal H-6a, H-1), 3.70-3.75 (m, 3H, Fuc H-2, Fuc H-4, Gal H-6b), 3.85 (dd, 3J=3.3, 10.3 Hz, 1H, Fuc H-3), 3.88 (m, 1H, Gal H-4) 4.07 (dd, 3J=3.1, 9.3 Hz, 1H, Lac H-2), 4.29 (d, 3J=7.8 Hz, 1H, Gal H-1), 4.89 (m, 1H, Fuc H-5), 5.00 (d, 3J=3.9 Hz, 1H, Fuc H-1); elemental analysis calcd (%) for C28H47NaO13.1H2O (614.65+18.02): C, 53.16; H, 7.81. found: C, 53.22; H, 7.91.
    • Example 3 {(1R,2R,3S)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-yl}2-O-benzyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (A-VIII; FIG. 3)
  • General Procedure a for Nucleophilic Opening of Epoxide A-I with Cuprate Reagents.
  • CuCN (3.81 mmol) was dried in vacuo at 150° C. for 30 min, suspended in dry THF (10 mL) and cooled to −78° C. A solution of the appropriate organo lithium compound (7.63 mmol) was slowly added via syringe and the temperature was raised over a period of 30 min to −20° C. and the mixture stirred at this temperature for 10 min. The mixture was cooled to −78° C. followed by the addition of freshly distilled BF3 etherate (1.53 mmol) in THF (2 mL). After stirring for 20 min, epoxide A-I (0.761 mmol) dissolved in THF (8 mL) was added. The reaction was slowly warmed to −50° C. over 5 h and then stirred at this temperature for 24 h. After slowly warming the reaction to −30° C. over another 21 h the reaction was quenched with a 25% aq. NH3/satd. NH4Cl (1:9, 20 mL) solution. The mixture was transferred with Et2O (30 mL) into a separation funnel and extracted with additional 25% aq. NH3/satd. NH4Cl (1:9, 30 mL) solution. The layers were separated and the organic layer was washed with brine (50 mL). The aqueous layers were extracted with Et2O (2×30 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/Et2O, 20:1 to 13:1, +1% Et3N) to afford the corresponding GlcNAc mimic.
    • General Procedure B for α-Fucosylation and Detritylation.
  • A solution of Br2 (0.837 mmol) in CH2Cl2 (1 mL) was added dropwise at 0° C. to a solution of ethyl 2,3,4-tri-O-benzyl-1-thio-L-fucopyranoside (A-III, 0.729 mmol) in CH2Cl2 (2 mL). After stirring for 50 min at 0° C., cyclohexene (100 μL) was added and the solution stirred for another 20 min. The mixture was added dropwise to a solution of the appropriate GlcNAc mimic (0.558 mmol) and Et4NBr (0.733 mmol) in DMF/CH2Cl2 (10 mL, 1:1), which has been stirred with activated 3 Å molecular sieves (850 mg) for 2 h. The mixture was stirred for 14 h at r.t. The reaction was quenched with pyridine (1 mL) and filtered over celite with addition of CH2Cl2 (20 mL). The solution was washed with brine (40 mL) and the aqueous layer was extracted with CH2Cl2 (3×30 mL). The combined organic phases were dried with Na2SO4, filtered and the solvents were removed azeotropically with toluene. The residue was purified by flash chromatography (petroleum ether/diethyl ether, 12:1 to 7:1, +1% Et3N) to afford the fucosylated tritylether. To a stirred solution of the tritylether (0.305 mmol) in CH2Cl2 (4 mL), ZnBr2 (0.924 mmol) and triethylsilane (0.344 mmol) were added. The reaction was quenched after 8 h by adding water (100 μL). CH2Cl2 (10 mL) was added and the reaction mixture extracted with satd. aqueous NaHCO3 (30 mL). The aqueous layer was extracted with DCM (2×20 mL). The combined organic layers were washed with satd. aqueous NaHCO3 (50 mL) and the aqueous layer was extracted with DCM (2×50 mL). The combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo. Chromatographic purification of the crude product (petroleum ether/toluene/ethyl acetate, 7:7:1 to 4:4:1) afforded the corresponding disaccharide mimic.
    • General Procedure C for DMTST Promoted Glycosylations.
  • A solution of the thioglycoside A-VI (0.292 mmol) and the appropriate glycosyl acceptor (0.225 mmol) in dry CH2Cl2 (8 mL) was added via syringe to activated 3 Å molecular sieves (2 g) under argon. A suspension of dimethyl(methylthio)sulfonium triflate (DMTST) (0.685 mmol) and activated 3 Å molecular sieves (1 g) in CH2Cl2 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (2 ml). The reaction was stopped after 2 d, filtered through celite and the celite washed with CH2Cl2 (10 mL). The filtrate was successively washed with satd. aqueous NaHCO3 (25 mL) and water (40 mL). The aqueous layers were extracted with CH2Cl2 (3×25 mL). The combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography (petroleum ether/toluene/ethyl acetate, 10:10:1 to 5:5:1) to afford the corresponding tetrasaccharide mimic as a colorless foam.
  • General Procedure D for Deprotection with Pd(Oh)2/C and Sodium Methoxide.
  • Pd(OH)2/C (50 mg, 10% Pd) was suspended under argon in dioxane/H2O (4:1, 3.75 mL). The appropriate protected compound (77.7 μmol) was added and the resulting mixture was hydrogenated under 70 psi at r.t. After 24 h the mixture was filtered through celite and reacted with fresh Pd(OH)2/C (50 mg) for additional 48 h, until TLC control indicated completion of the reaction. The reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (0.194 mmol in 190 μl MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (22 μL). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford the corresponding antagonists as colorless solids.
    • (1R,2R,3R)-3-Ethenyl-1-O-triphenylmethyl-cyclohexane-1,2-diol (A-II)
  • A vinyl lithium solution was generated in situ by treating a solution of tetravinyl tin (409 μL, 2.25 mmol) in THF (3 mL) with nBuLi (2.5 M in hexane, 3.35 mL, 8.38 mmol) during 30 min at 0° C. CuCN (373 mg, 4.16 mmol) in THF (8 mL) was treated with the vinyl lithium solution and BF3 etherate (209 μL, 1.66 mmol) in THF (1.5 mL) according to general procedure A. Epoxide A-I (296 mg, 0.830 mmol) in THF (8 mL) was slowly added and the reaction slowly warmed to −30° C. (−78° C.: 15 min; −78° C. to −50° C.: 1.5 h; −50°: 13 h; −50° C. to −30° C.: 1.5 h; −30° C.: 24 h). Work-up and purification according to general procedure A yielded A-II (258 mg, 81%) as a yellowish resin.
  • [α]D 21−33.7 (c=0.53, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.84 (m, 1H, H-5a), 1.15 (m, 1H, H-4a), 1.32 (m, 1H, H-6a), 1.43-1.55 (m, 3H, H-5b, H-6b, H-4b), 1.81 (m, 1H, H-3), 2.66 (s, 1H, OH), 2.91 (ddd, 3J=3.9, 8.6, 11.3 Hz, 1H, H-1), 3.51 (t, 3J=9.3 Hz, 1H, H-2), 5.02 (A of ABX, 3JA,X=10.4 Hz, 2JA,B=1.7 Hz, 3JA,3=0.7 Hz, 1H, vinyl HA), 5.04 (B of ABX, 3JB,X=17.2 Hz, 2JA,B=1.7 Hz, 3JB,3=0.7 Hz, 1H, vinyl HB), 5.83 (X of ABX, 3JA,X=10.4 Hz, 3JB,X=17.2 Hz, 3JX,3=7.6 Hz, 1H, vinyl HX), 7.21-7.31, 7.48-7.50 (2 m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 23.18 (C-5), 30.39 (C-4), 32.21 (C-6), 47.30 (C-3), 76.74 (C-2), 78.53 (C-1), 114.77 (vinyl C), 127.11, 127.77, 128.75, 145.07 (18C, 3C6H5), 140.57 (vinyl C); IR (film on NaCl) ν: 3577 (m, OH), 3059 (m), 2932 (vs), 2860 (s), 1641 (vw), 1597 (vw), 1489 (s), 1448 (s), 1278 (m), 1225 (m), 1152 (w), 1064 (vs), 991 (s), 915 (m) cm−1; elemental analysis calcd (%) for C27H28O2 (384.51): C, 84.34; H, 7.34. found: C, 84.15; H, 7.33.
    • [(1R,2R,3R)-3-Ethenyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (A-IV)
  • According to general procedure B, A-III (205 mg, 0.428 mmol) in CH2Cl2 (1.5 mL) was treated with a solution of Br2 (25.5 μL, 0.496 mmol) in CH2Cl2 (1 mL) for 40 min at 0° C. After destroying the excess of bromine, the fucosyl bromide solution was added to a solution of A-II (126 mg, 0.329 mmol) and Et4NBr (90.8 mg, 0.432 mmol) in DMF/CH2Cl2 (6 mL, 1:1), which has been stirred with activated 3 Å molecular sieves (500 mg) for 4 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-up and purification according to general procedure B yielded the tritylether (213 mg). To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (179 mg, 0.793 mmol) and triethylsilane (63 μL, 0.397 mmol) were added. The reaction was quenched after 2 h by adding H2O (100 μL). Work-up and purification according to general procedure B yielded A-IV (110 mg, 60% over two steps) as a colorless solid.
  • [α]D 21=−22.1 (c=0.52, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 1.15 (d, 3JF6,F5=6.5 Hz, 3H, Fuc H-6), 1.17 (m, 1H, H-4a), 1.26-1.30 (m, 2H, H-5a, H-6a), 1.72 (m, 1H, H-5b), 1.78 (m, 1H, H-4b), 2.02 (m, 1H, H-6b), 2.13 (m, 1H, H-3), 3.04 (t, 3J=9.5 Hz, 1H, H-2), 3.45 (m, 1H, H-1), 3.69 (m, 1H, Fuc H-4), 3.98 (dd, 3JF3,F4=2.6 Hz, 3JF2,F3=10.1 Hz, 1H, Fuc H-3), 4.10 (dd, 3JF1,F2=3.6 Hz, 3JF2,F3=10.1 Hz, 1H, Fuc H-2), 4.12 (m, 1H, Fuc H-5), 4.65, 4.70, 4.76, 4.78, (4 m, 4H, 2 CH2Ph), 4.85 (m, 2H, CH2Ph, vinyl H), 4.98 (m, 1H, vinyl H), 4.99 (m, 1H, CH2Ph), 5.03 (d, 3JF1,F2=3.6 Hz, 1H, Fuc H-1), 6.25 (m, 1H, vinyl H), 7.27-7.40 (m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.55 (Fuc C-6), 22.81 (C-5), 29.67 (C-4), 32.39 (C-6), 44.33 (C-3), 67.56 (Fuc C-5), 72.97, 73.01 (CH2Ph, C-1), 73.38, 74.85 (2 CH2Ph), 76.41 (Fuc C-2), 77.54 (Fuc C-4), 78.86 (Fuc C-3), 90.26 (C-2), 97.98 (Fuc C-1), 113.46 (vinyl C), 127.43, 127.48, 127.53, 127.63, 127.82, 128.23, 128.36 (18C, 3 C6H5), 140.43 (vinyl C), IR (KBr) ν: 3429 (s, OH), 3065 (w), 3031 (w), 2932 (s), 2866 (s), 1636 (vw), 1497 (w), 1454 (m), 1348 (m), 1308 (w), 1246 (vw), 1212 (w), 1161 (s), 1138 (s), 1101 (vs), 1064 (vs), 1027 (vs), 953 (m), 911 (w) cm−1; elemental analysis calcd (%) for C35H42O6 (558.70): C, 75.24; H, 7.58. found: C, 74.91; H, 7.55.
    • [(1R,2R,3S)-3-Ethyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (A-V)
  • A solution of A-IV (90.0 mg, 0.161 mmol) in THF (4 mL) was added to Pd/C (45.2 mg, 10% Pd) under argon. The mixture was hydrogenated under atmospheric pressure at r.t. After 30 min the reaction was filtered through celite, concentrated under reduced pressure and purified by column chromatography (toluene/petroleum ether/ethyl acetate, 7:7:1 to 5:5:1) to yield A-V (69.8 mg, 77%) as a colorless solid.
  • [α]D 21=−37.2 (c=0.50, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.78 (t, 3J=7.5 Hz, 3H, CH2CH3), 0.88 (m, 1H, H-4a), 1.06-1.26 (m, 3H, CH2CH3, H-5a, H-6a), 1.16 (d, 3JF5,F6=6.5 Hz, 3H, Fuc H-6), 1.30 (m, 1H, H-3), 1.67 (m, 1 H, H-5b), 1.79 (m, 1H, H-4b), 1.99-2.07 (m, 2H, H-6b, CH2CH3), 2.96 (dd, 3J=8.6, 10.2 Hz, 1H, H-2), 3.38 (ddd, 3J=4.8, 8.5, 10.6 Hz, 1H, H-1), 3.70 (m, 1H, Fuc H-4), 3.98 (dd, 3JF3,F4=2.7 Hz, 3JF3,F2=10.2 Hz, 1H, Fuc H-5), 4.10-4.14 (m, 2H, Fuc H-2, Fuc H-5), 4.66, 4.70, 4.77, 4.80, 4.84 (5 m, 5H, CH2Ph), 4.89-5.00 (m, 2 H, Fuc H-1, CH2Ph), 7.27-7.40 (m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 10.99 (CH2CH3), 16.60 (Fuc C-6), 23.09 (C-5), 24.17 (CH2CH3), 29.50 (C-4), 32.60 (C-6), 42.64 (C-3), 67.48 (Fuc C-5), 72.83, 73.13, 73.47 (C-1, 2 CH2Ph), 74.84 (CH2Ph), 76.32 (Fuc C-2), 77.37 (Fuc C-4), 78.86 (Fuc C-3), 91.07 (C-2), 98.31 (Fuc C-1), 127.40, 127.46, 127.50, 127.64, 127.80, 128.21, 128.33, 128.39, 138.31, 138.39, 138.70 (18C, 3 C6H5); HR-MS (ESI) m/z: calcd for C35H44NaO6 [M+Na]+: 583.3030. found: 583.3018 (2.1 ppm).
    • {(1R,2R,3S)-2-[(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-yl}2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-β-D-galactopyranoside (A-VII)
  • According to general procedure C, thioglycoside A-VI (112 mg, 0.144 mmol) and glycosyl acceptor A-V (61.6 mg, 0.110 mmol) in dry CH2Cl2 (4 mL) were added via syringe to activated 3 Å molecular sieves (1 g). A suspension of DMTST (87.0 mg, 0.337 mmol) and activated 3 Å molecular sieves (500 mg) in CH2Cl2 (2 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (1 mL). The reaction was stopped after 49.5 h and work-up and purification according to general procedure C afforded A-VII (110 mg, 78%) as a colorless foam.
  • [α]D 21=−51.5 (c=0.42, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.45-1.61 (m, 20H, CyCH2, EtCy), 0.75 (t, 3J=7.3 Hz, 3H, CH2CH3), 1.41 (d, 3JF5,F6=6.4 Hz, 3H, Fuc H-6), 1.84 (m, 1H, H-6b), 1.92 (m, 1H, CH2CH3), 3.31 (t, 3J=8.7 Hz, 1H, H-2), 3.49-3.52 (m, 2H, H-1, Fuc H-4), 3.82 (dd, 3JG3,G4=3.2 Hz, 3JG2,G3=9.8 Hz, 1H, Gal H-3), 3.92 (m, 1H, Gal H-5), 3.99-4.05 (m, 2H, Fuc H-2, Fuc H-3), 4.12 (dd, 3J=4.6, 7.9 Hz, 1H, Lac H-2), 4.25 (dd, 3JG5,G6a=7.2 Hz, 3JG6a,G6b=11.4 Hz, 1H, Gal H-6a), 4.28 (m, 1H, CH2Ph), 4.39 (dd, 3JG5,G6b=5.7 Hz, 3JG6a,G6b=11.4 Hz, 1H, Gal H-6b), 4.51-4.55 (m, 2H, CH2Ph, Gal H-1), 4.63, 4.65, 4.75, 4.78 (4 m, 4H, CH2Ph), 4.81 (m, 1H, Fuc H-5), 4.98 (d, 3JF1,F2=2.8 Hz, 1H, Fuc H-1), 5.04, 5.11 (2 m, 2H, CH2Ph), 5.60 (m, 1H, Gal H-2), 5.84 (m, 1 H, Gal H-4), 7.17-7.33, 7.42-7.46, 7.52-7.58, 8.04-8.12 (4 m, 35H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 10.94 (CH2CH3), 16.82 (Fuc C-6), 23.18 (CH2CH3), 22.11, 25.45, 25.71, 26.07, 27.89, 30.41, 32.60, 33.19, 33.40, 40.49 (10C, EtCy, CyCH2), 44.71 (C-3), 62.50 (Gal C-6), 66.35 (Fuc C-5), 66.64 (CH2Ph), 70.17 (Gal C-4), 71.40 (Gal C-5), 72.07 (CH2Ph), 72.17 (Gal C-2), 74.29, 74.91 (2 CH2Ph), 76.42 (Fuc C-2), 78.06 (Gal C-3), 78.38 (Lac C-2), 79.22, 79.27 (Fuc C-4, C-2), 79.77 (Fuc C-3), 80.95 (C-1), 97.96 (Fuc C-1), 100.05 (Gal C-1), 126.94, 127.06, 127.21, 127.39, 127.77, 128.05, 128.10, 128.38, 128.44, 128.50, 128.54, 129.66, 129.93, 133.03, 133.17, 133.27, 135.40, 138.64, 139.01, 139.17 (42C, 7C6H5), 164.58, 166.11, 166.22, 172.48 (4C═O); elemental analysis calcd (%) for C78H86O16 (1279.51)+½H2O: C, 72.20; H, 6.84. found: C, 72.37; H, 6.82; HR-MS (ESI) m/z: calcd for C78H86NaO16 [M+Na]+: 1301.5808. found: 1301.5855 (3.6 ppm).
    • {(1R,2R,3S)-2-[6-deoxy-α-L-galactopyranosyl)oxy]-3-ethyl-cyclohex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (A-VIII; FIG. 3).
  • A-VII (38.2 mg, 29.9 μmol) was hydrogenated with Pd(OH)2/C (50 mg, 10% Pd) in dioxane/H2O (4:1, 3.75 mL) according to general procedure D. After 24 h the reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (74.6 μmol in 73 μl MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (8.5 μL). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford A-VIII (16.3 mg, 77%) as a colorless solid.
  • [α]D 21=−89.3 (c=0.47, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.55-1.69 (m, 20H, CyCH2, EtCy), 0.83 (t, 3J=7.3 Hz, 3H, CH2CH3), 1.32 (d, 3J=6.6 Hz, 3H, Fuc H-6), 1.90 (m, 1H, CH2CH3), 1.99 (m, 1H, H-6b), 3.24 (t, 3J=8.9 Hz, 1H, H-2), 3.57 (m, 1H, Gal H-5), 3.62 (m, 1H, H-1), 3.67 (dd, 3JG3,G4=3.0 Hz, 3JG2,G3=9.8 Hz, 1H, Gal H-3), 3.70-3.75 (m, 3H, Gal H-6a, Fuc H-2, Fuc H-4), 3.79 (dd, 3JG5,G6b=6.9 Hz, 2JG6a,G6b=11.3 Hz, 1H, Gal H-6b), 3.86 (dd, 3JF3,F4=3.3 Hz, 3JF2,F3=10.3 Hz, 1H, Fuc H-3), 3.97 (m, 1H, Gal H-4), 4.07 (dd, 3J=3.0, 9.8 Hz, 1H, Lac H-2), 4.67 (d, 3JG1,G2=8.1 Hz, 1H, Gal H-1), 4.90 (m, 1H, Fuc H-5), 4.91 (m, 1H, Fuc H-1), 5.43 (dd, 3JG1,G2=8.3 Hz, 3JG2,G3=9.4 Hz, 1H, Gal H-2), 7.49-7.52, 7.61-7.64, 8.08-8.09 (3 m, 5H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 11.12 (CH2CH3), 16.72 (Fuc C-6), 23.39, 24.59, 26.54, 26.72, 27.27, 29.47, 31.86, 33.14, 34.20, 35.06, 42.76 (11C, EtCy, CH2Cy), 45.96 (C-3), 62.68 (Gal C-6), 67.77 (Fuc C-5), 67.83 (Gal C-4), 70.30 (Fuc C-2), 71.38 (Fuc C-3), 73.12 (Gal C-2), 73.92 (Fuc C-4), 75.90 (Gal C-5), 77.94 (Lac C-2), 80.77 (C-1), 81.11 (C-2), 83.55 (Gal C-3), 100.20 (Fuc C-1), 100.52 (Gal C-1), 129.67, 130.84, 131.63, 134.37 (6C, C6H5), 166.79 (C═O), 178.76 (CO2H); HR-MS (ESI) m/z: calcd for C36H54NaO14 [M+Na]+: 733.3406. found: 733.3409 (0.4 ppm).
    • Example 4 {(1R,2R,3R)-3-cyclopropyl-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-cyclohex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (B-IV; FIG. 4) (1R,2R,3R)-3-Cyclopropyl-1-O-triphenylmethyl-cyclohexane-1,2-diol (B-I)
  • A cPrLi solution was generated in situ by treating a solution of bromocyclopropane (370 μL, 4.63 mmol) in THF (4 mL) with tBuLi (1.7 M in pentane, 5.45 mL, 9.27 mmol) during 80 min at −78° C. CuCN (210 mg, 2.34 mmol) in THF (5 mL) was treated with the cPrLi solution and BF3 etherate (115 μL, 0.914 mmol) in THF (1 mL) according to general procedure A. Epoxide A-I (165 mg, 0.463 mmol) in THF (5 mL) was slowly added and the reaction slowly warmed to −30° C. (−78° C.: 1.5 h; −78° C. to −50° C.: 1.5 h; −50°: 24 h; −50° C. to −30° C.: 40 min). Work-up and purification according to general procedure A yielded B-I (150.7 mg, 82%).
  • [α]D 21=−38.8 (c=0.50, CH2Cl2); 1H-NMR (CD2Cl2, 500.1 MHz) δ: −0.16 (m, 1H, cPr), 0.13-0.23 (m, 2H, cPr), 0.34-0.43 (m, 2H, cPr, H-3), 0.54-0.67 (m, 2H, cPr, H-5a), 0.91 (m, 1H, H-4a), 1.18 (m, 1H, H-6a), 1.27-1.35 (m, 2H, H-5b, H-6b), 1.44 (m 1H, H-4b), 2.52 (s, 1H, OH), 2.71 (ddd, 3J=4.1, 8.6, 11.0 Hz, 1H, H-1), 3.47 (t, 3J=9.1 Hz, 1H, H-2), 7.15-7.23, 7.42-7.43 (2 m, 15H, 3 C6H5); 13C-NMR (CD2Cl2, 125.8 MHz) δ: 0.85, 4.26, 14.56 (3C, cPr), 23.11 (C-5), 29.50 (C-4), 32.15 (C-6), 46.68 (C-3), 78.55 (C-2), 78.92 (C-1), 86.37 (OCPh3), 127.07, 127.73, 128.82, 145.37 (18C, 3 C6H5); IR (KBr) ν: 3571 (m, OH), 3058 (w), 2930 (m), 2858 (m), 1596 (vw), 1490 (m), 1448 (s), 1284 (w), 1225 (w), 1152 (w), 1063 (vs), 926 (w), 844 (vw), 824 (vw), 761 (m), 746 (m), 707 (vs) cm−1; elemental analysis calcd (%) for C28H30O2 (398.54): C, 84.38; H, 7.59. found: C, 84.16; H, 7.78.
    • [(1R,2R,3R)-3-Cyclopropyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (B-II)
  • According to general procedure B, A-III (223 mg, 0.466 mmol) in CH2Cl2 (1.5 mL) was treated with a solution of Br2 (27.5 μL, 0.535 mmol) in CH2Cl2 (1 mL) for 30 min at 0° C. After destroying the excess of bromine, the fucosyl bromide solution was added to a solution of B-I (142 mg, 0.356 mmol) and Et4NBr (98.9 mg, 0.471 mmol) in DMF/CH2Cl2 (6 mL, 1:1), which has been stirred with activated 3 Å molecular sieves (1 g) for 4 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-up and purification according to general procedure B yielded the tritylether (237 mg). To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (193 mg, 0.859 mmol) and triethylsilane (70 μL, 0.441 mmol) were added. The reaction was quenched after 1.75 h by adding H2O (100 μL). Work-up and purification according to general procedure B yielded B-II (136 mg, 67% over two steps) as a colorless solid.
  • [α]D 21=−29.0 (c=0.65, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: −0.06 (m, 1H, cPr), 0.08 (m, 1H, cPr), 0.22 (m, 1H, cPr), 0.33 (m, 1H, cPr), 0.87 (m, 1H, H-4a), 0.96 (m, 1H, cPr), 1.05-1.27 (m, 6H, Fuc H-6, H-3, H-5a, H-6a), 1.54 (m, 1H, H-4b), 1.64 (m, 1H, H-5b), 1.96 (m, 1H, H-6b), 3.11 (t, 3J=9.1 Hz, 1H, H-2), 3.35 (m, 1H, H-1), 3.69 (m, 1H, Fuc H-4), 3.98 (dd, 3JF3,F4=2.5 Hz, 3JF2,F3=10.1 Hz, 1H, Fuc H-3), 4.11-4.16 (m, 2H, Fuc H-2, Fuc H-5), 4.66-4.68 (m, 2H, CH2Ph), 4.76, 4.77, 4.90, 5.01 (4 m, 4H, CH2Ph), 5.14 (d, 3JF1,F2=3.4 Hz, 1H, Fuc H-1), 7.26-7.41 (m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 0.76, 4.93, 13.58 (3C, cPr), 16.56 (Fuc C-6), 22.86 (C-5), 28.32 (C-4), 32.56 (C-6), 44.14 (C-3), 67.64 (Fuc C-5), 73.14, 73.19 (2 CH2Ph), 73.95 (C-1), 74.85 (CH2Ph), 76.74 (Fuc C-2), 77.68 (Fuc C-4), 78.63 (Fuc C-3), 92.33 (C-2), 99.20 (Fuc C-1), 127.42, 127.45, 127.50, 127.64, 128.18, 128.22, 128.35, 128.44, 138.44, 138.58, 138.90 (18C, 3 C6H5); IR (KBr) ν: 3426 (s, OH), 3031 (vw), 3004 (vw), 2933 (s), 1497 (vw), 1453 (m), 1348 (w), 1247 (vw), 1212 (vw), 1161 (m), 1136 (s), 1103 (vs), 1064 (vs), 1026 (vs), 957 (w), 911 (vw), 843 (vw), 736 (s), 696 (s) cm−1; elemental analysis calcd (%) for C36H44O6 (572.73): C, 75.50; H, 7.74. found: C, 75.38; H, 7.75.
    • {(1R,2R,3R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-cyclopropyl-cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-β-D-galactopyranoside (B-III)
  • According to general procedure C, thioglycoside A-VI (228 mg, 0.292 mmol) and glycosyl acceptor B-II (129 mg, 0.225 mmol) in dry CH2Cl2 (8 mL) were added via syringe to activated 3 Å molecular sieves (2 g). A suspension of DMTST (177 mg, 0.685 mmol) and activated 3 Å molecular sieves (1 g) in CH2Cl2 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (2 mL). The reaction was stopped after 48 h and work-up and purification according to general procedure C afforded B-III (253 mg, 87%) as a colorless foam.
  • [α]D 21=−43.1 (c=0.61, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: −0.11 (m, 1H, cPr), 0.16 (m, 1H, cPr), 0.32-0.35 (m, 2H, cPr), 0.46-0.53 (m, 2H, CyCH2), 0.64-1.46 (m, 18H, CyCH2, Cy, cPr), 1.38 (d, 3JF5,F6=6.4 Hz, 3H, Fuc H-6), 1.80 (m, 1H, H-6b), 3.52 (t, 3J=7.3 Hz, 1H, H-2), 3.57 (s, 1H, Fuc H-4), 3.62 (m, 1H, H-1), 3.84 (dd, 3JG3,G4=2.8 Hz, 3JG2,G3=9.8 Hz, 1H, Gal H-3), 3.93 (m, 1H, Gal H-5), 4.03 (dd, 3JF1,F2=3.2 Hz, 3JF2,F3=10.2 Hz, 1H, Fuc H-2), 4.07 (dd, 3JF3,F4=1.7 Hz, 3JF2,F3=10.4 Hz, 1H, Fuc H-3), 4.13 (dd, 3J=4.5, 7.8 Hz, 1 H, Lac H-2), 4.32-4.40 (m, 3H, Gal H-6, CH2Ph), 4.53 (m, 1H, CH2Ph), 4.58 (d, 3JG1,G2=8.1 Hz, 1H, Gal H-1), 4.62, 4.68 (2 m, 2H, CH2Ph), 4.74-4.76 (m, 2H, Fuc H-5, CH2Ph), 4.78 (m, 1H, CH2Ph), 5.05, 5.11 (2 m, 2H, CH2Ph), 5.35 (d, 3JF1,F2=2.8 Hz, 1H, Fuc H-1), 5.61 (m, 1H, Gal H-2), 5.87 (m, 1H, Gal H-4), 7.20-7.36, 7.42-7.44, 7.52-7.59, 8.03-8.14 (4 m, 35H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 3.06 (cPr), 5.26 (cPr), 13.55 (cPr), 16.81 (Fuc C-6), 20.97, 25.46, 25.72, 26.07, 27.71, 29.44, 32.62, 33.21, 33.40 (9C, CyCH2, Cy), 40.46 (Lac C-3), 45.35 (C-3), 62.50 (Gal C-6), 66.34 (Fuc C-5), 66.61 (CH2Ph), 70.10 (Gal C-4), 71.49 (Gal C-5), 72.13 (CH2Ph), 72.32 (Gal C-2), 74.22 (CH2Ph), 74.87 (CH2Ph), 76.15 (Fuc C-2), 77.97 (Gal C-3), 78.38 (Lac C-2), 78.82 (C-2), 79.13 (Fuc C-4), 79.66 (C-1), 79.83 (Fuc C-3), 97.02 (Fuc C-1), 99.60 (Gal C-1), 126.96, 127.05, 127.20, 127.38, 127.78, 128.05, 128.09, 128.37, 128.43, 128.47, 128.53, 129.61, 129.73, 129.89, 129.93, 129.96, 133.03, 133.16, 133.23, 135.44, 138.51, 138.95, 139.21 (42C, 7 C6H5), 164.57, 165.98, 166.16, 172.43 (4C═O); IR (KBr) ν: 3064 (vw), 3032 (vw), 2927 (s), 2854 (w), 1731 (vs, C═O), 1602 (vw), 1497 (vw), 1452 (m), 1315 (m), 1267 (vs), 1176 (s), 1097 (vs), 1027 (vs), 840 (vw), 713 (vs) cm−1; elemental analysis calcd (%) for C79H86O16 (1291.52): C, 73.47; H, 6.71. found: C, 73.32; H, 6.81.
    • {(1R,2R,3R)-3-cyclopropyl-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (B-IV; FIG. 4)
  • B-III (100 mg, 77.7 μmol) was hydrogenated with Pd(OH)2/C (52 mg, 10% Pd) in dioxane/H2O (4:1, 3.75 mL) according to general procedure D. After 24 h the mixture was filtered through celite and hydrogenated with fresh Pd(OH)2/C (50 mg) for another 48 h. The reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (194 μmol in 190 μl MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (22 μL). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford B-IV (40.5 mg, 72%) as a colorless solid.
  • [α]D 21=−85.4 (c=0.75, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: −0.04 (m, 1H, cPr), 0.33 (m, 1H, cPr), 0.45-0.52 (m, 2H, cPr), 0.56-1.65 (m, 20 H, CyCH2, cPrCy), 1.30 (d, 3JF5,F6=6.6 Hz, 3H, Fuc H-6), 1.94 (m, 1H, H-6b), 3.45 (t, 3J=8.5 Hz, 1H, H-2), 3.56 (m, 1H, Gal H-5), 3.62 (m, 1H, H-1), 3.66 (dd, 3JG3,G4=3.1 Hz, 3JG2,G3=9.8 Hz, 1H, Gal H-3), 3.71-3.74 (m, 2H, Gal H-6a, Fuc H-2), 3.78 (m, 1H, Fuc H-4), 3.83 (dd, 3JG5,G6b=7.1 Hz, 2JG6a,G6b=11.4 Hz, 1H, Gal H-6b), 3.95 (dd, 3JF3,F4=3.3 Hz, 3JF2,F3=10.2 Hz, 1H, Fuc H-3), 3.97 (m, 1H, Gal H-4), 4.06 (dd, 3J=2.9, 9.8 Hz, 1H, Lac H-2), 4.66 (d, 3JG1,G2=8.0 Hz, 1H, Gal H-1), 4.88 (m, 1H, Fuc H-5), 5.37 (d, 3JF1,F2=3.9 Hz, 1H, Fuc H-1), 5.39 (dd, 3JG1,G2=8.1 Hz, 3JG2,G3=9.6 Hz, 1H, Gal H-2), 7.49-7.52, 7.61-7.65, 8.07-8.09 (3 m, 5H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 3.96, 7.18, 15.53 (3C, cPr), 16.72 (Fuc C-6), 22.94, 26.54, 26.73, 27.27, 30.78, 31.45 (6C, CyCH2, Cy), 33.13, 34.20, 35.07, 42.76 (4C, CyCH2), 48.49 (C-3), 62.72 (Gal C-6), 67.61 (Fuc C-5), 67.88 (Gal C-4), 70.24 (Fuc C-2), 71.34 (Fuc C-3), 73.16 (Gal C-2), 73.97 (Fuc C-4), 76.02 (Gal C-5), 78.01 (Lac C-2), 80.29 (C-1), 80.52 (C-2), 83.45 (Gal C-3), 98.97 (Fuc C-1), 100.41 (Gal C-1), 129.66, 130.82, 131.63, 134.36 (6C, C6H5), 166.76 (C═O), 178.83 (CO2H); HR-MS (ESI) m/z: calcd for C37H54NaO14[M+Na]+: 745.3406. found: 745.3407 (0.1 ppm).
    • Example 5 {(1R,2R,3S)-3-butyl-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside sodium salt (C-IV; FIG. 5) (1R,2R,3S)-3-Butyl-1-O-triphenylmethyl-cyclohexane-1,2-diol (C-I)
  • CuCN (342 mg, 3.81 mmol) in THF (10 mL) was treated with nBuLi (2.5 M in hexane, 3.05 mL, 7.63 mmol) and BF3 etherate (192 μL, 1.53 mmol) in THF (2 mL) according to general procedure A. Epoxide A-I (271 mg, 0.761 mmol) in THF (8 mL) was slowly added and the reaction slowly warmed to −30° C. (−78° C.: 1 h; −78° C. to −50° C.: 4 h; −50°: 24 h; −50° C. to −30° C.: 21 h). Work-up and purification according to general procedure A yielded C-I (220 mg, 70%).
  • [α]D 21=−37.8 (c=0.66, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.73 (m, 1H, H-5a), 0.85 (m, 1H, H-4a), 0.86 (t, 3J=7.2 Hz, 3H, H-10), 1.03-1.16 (m, 3 H, H-3, H-7a, H-8a), 1.21-1.35 (m, 4H, H-6a, H-8b, H-9a, H-9b), 1.38-1.49 (m, 2H, H-5b, H-6b), 1.61 (m, 1H, H-4b), 1.75 (m, 1H, H-7b), 2.70 (s, 1H, OH), 2.82 (ddd, 3J=4.0, 8.6, 11.2 Hz, 1H, H-1), 3.40 (t, 3J=9.0 Hz, 1H, H-2), 7.21-7.30, 7.48-7.50 (2 m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 14.11 (C-10), 23.10 (C-9), 23.37 (C-5), 28.73 (C-8), 29.38 (C-4), 32.05 (C-7), 32.30 (C-6), 42.45 (C-3), 77.62 (C-2), 79.05 (C-1), 86.43 (CPh3), 127.05, 127.74, 128.70, 145.12 (18C, 3 C6H5); elemental analysis calcd (%) for C29H34O2 (414.58): C, 84.02; H, 8.27. found: C, 84.05; H, 8.27.
    • [(1R,2R,3S)-3-Butyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (C-II)
  • According to general procedure B, A-III (308 mg, 0.644 mmol) in CH2Cl2 (3 mL) was treated with a solution of Br2 (38 μL, 0.740 mmol) in CH2Cl2 (1 mL) for 30 min at 0° C. After destroying the excess of bromine, the fucosyl bromide solution was added to a solution of C-I (205 mg, 0.495 mmol) and Et4NBr (137 mg, 0.650 mmol) in DMF/CH2Cl2 (10 mL, 1:1), which has been stirred with activated 3 Å molecular sieves (700 mg) for 3.5 h. The reaction was stirred for 67 h at r.t. and then quenched with pyridine (1 mL). Work-up and purification according to the general procedure B yielded the tritylether (283 mg) as a yellowish resin. To a stirred solution of the tritylether in CH2Cl2 (4 mL), ZnBr2 (229 mg, 1.02 mmol) and triethylsilane (81 μL, 0.510 mmol) were added. The reaction was quenched after 1.25 h by adding H2O (100 μL). Work-up and purification according to general procedure B yielded C-II (161 mg, 55% over two steps) as a colorless solid.
  • [α]D 21=−21.3 (c=0.56, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.82 (t, 3J=7.0 Hz, 3H, H-10), 0.86 (m, 1H, H-4a), 0.98 (m, 1H, H-7a), 1.15 (d, 3JF5,F6=6.5 Hz, 3H, Fuc H-6), 1.09-1.37 (m, 7H, H-3, H-5a, H-6a, H-8a, H-8b, H-9a, H-9b), 1.66 (m, 1H, H-5b), 1.81 (m, 1H, H-4b), 1.98 (m, 1H, H-6b), 2.10 (m, 1H, H-7b), 2.94 (t, 3J=9.3 Hz, 1H, H-2), 3.36 (m, 1H, H-1), 3.68 (m, 1H, Fuc H-4), 3.98 (dd, 3JF3,F4=2.6 Hz, 3JF2,F3=10.2 Hz, 1H, Fuc H-3), 4.09-4.14 (m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.70, 4.75, 4.78, 4.85 (5 m, 5H, 3 CH2Ph), 4.98-5.00 (m, 2H, Fuc H-1, 1 CH2Ph), 7.25-7.39 (m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 14.11 (C-10), 16.57 (Fuc C-6), 22.72 (C-9), 23.19 (C-5), 29.03 (C-8), 30.26 (C-4), 31.24 (C-7), 32.55 (C-6), 41.18 (C-3), 67.54 (Fuc C-5), 72.97 (CH2Ph), 73.26 (C-1), 73.39 (CH2Ph), 74.84 (CH2Ph), 76.38 (Fuc C-2), 77.60 (Fuc C-4), 78.80 (Fuc C-3), 91.47 (C-2), 98.31 (Fuc C-1), 127.40, 127.45, 127.52, 127.61, 127.86, 128.20, 128.21, 128.33, 128.38, 138.32, 138.44, 138.79 (18C, 3 C6H5); elemental analysis calcd (%) for C37H48O6 (588.77): C, 75.48; H, 8.22. found: C, 75.55; H, 8.28.
    • {(1R,2R,3S)-2-[(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-butyl-cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-β-D-galactopyranoside (C-III)
  • According to general procedure C, thioglycoside A-VI (218 mg, 0.279 mmol) and glycosyl acceptor C-II (126 mg, 0.215 mmol) in dry CH2Cl2 (8 mL) were added via syringe to activated 3 Å molecular sieves (2 g). A suspension of DMTST (166 mg, 0.644 mmol) and activated 3 Å molecular sieves (1 g) in CH2Cl2 (4 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4.5 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (2 mL). The reaction was stopped after 65.5 h and work-up and purification according to general procedure C afforded C-III (224 mg, 80%) as a colorless foam.
  • [α]D 21=−46.7 (c=0.49, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.45-1.84 (m, 26H, CyCH2, nBuCy), 0.80 (d, 3J=6.8 Hz, 3H, nBu), 1.40 (d, 3J=6.5 Hz, 3H, Fuc H-6), 3.36 (t, 3J=8.5 Hz, 1H, H-2), 3.52 (s, 1H, Fuc H-4), 3.54 (m, 1H, H-1), 3.83 (dd, 3JG3,G4=3.0 Hz, 3JG2,G3=9.8 Hz, 1H, Gal H-3), 3.92 (m, 1H, Gal H-5), 4.01 (dd, 3JF1,F2=3.2 Hz, 3JF2,F3=10.3 Hz, 1H, Fuc H-2), 4.04 (dd, 3JF3,F4=2.0 Hz, 3JF2,F3=10.4 Hz, 1H, Fuc H-3), 4.13 (dd, 3J=4.6, 7.8 Hz, 1H, Lac H-2), 4.28 (dd, 3JG5,G6a=6.7 Hz, 2JG6a,G6b=11.4 Hz, 1H, Gal H-6a), 4.28 (m, 1 H, CH2Ph), 4.39 (dd, 3JG5,G6b=5.8 Hz, 2JG6a,G6b=11.4 Hz, 1H, Gal H-6b), 4.52 (m, 1H, CH2Ph), 4.56 (d, 3JG1,G2=8.1 Hz, 1H, Gal H-1), 4.65, 4.68, 4.74, 4.76 (4 m, 4 H, CH2Ph), 4.79 (m, 1H, Fuc H-5), 5.01 (d, 3JF1,F2=3.0 Hz, 1H, Fuc H-1), 5.05, 5.11 (2 m, 2H, CH2Ph), 5.61 (m, 1H, Gal H-2), 5.85 (m, 1H, Gal H-4), 7.20-7.36, 7.42-7.46, 7.52-7.59, 8.04-8.13 (4 m, 35H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 14.26 (CH2CH2CH2CH3), 16.81 (Fuc C-6), 21.84, 22.95, 25.46, 25.71, 26.07, 28.34, 28.55, 30.20, 30.39, 32.61, 33.19, 33.39, 40.48, 42.80 (14C, CyCH2, nBuCy), 62.52 (Gal C-6), 66.37 (Fuc C-5), 66.63 (CH2Ph), 70.15 (Gal C-4), 71.45 (Gal C-5), 72.11 (CH2Ph), 72.21 (Gal C-2), 73.89, 74.92 (2 CH2Ph), 76.17 (Fuc C-2), 78.05 (Gal C-3), 78.38 (Lac C-2), 78.76 (C-2), 79.23 (Fuc C-4), 79.75 (Fuc C-3), 80.79 (C-1), 97.71 (Fuc C-1), 100.03 (Gal C-1), 126.95, 127.04, 127.21, 127.30, 127.80, 128.04, 128.09, 128.15, 128.39, 128.44, 128.48, 128.49, 128.54, 129.66, 129.71, 129.75, 129.92, 129.94, 133.03, 133.16, 133.25, 135.42, 138.70, 138.99, 139.16 (42C, 7 C6H5), 164.56, 166.09, 166.21, 172.47 (4C═O); elemental analysis calcd (%) for C80H90O16 (1307.58): C, 73.49; H, 6.94. found: C, 73.16; H, 6.93.
    • {(1R,2R,3S)-3-butyl-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside sodium salt (C-IV; FIG. 5)
  • C-III (100 mg, 76.5 μmol) was hydrogenated with Pd(OH)2/C (50 mg, 10% Pd) in dioxane/H2O (4:1, 3.75 mL) according to general procedure D. After 19 h the mixture was filtered through celite and hydrogenated with fresh Pd(OH)2/C (50 mg) for another 30 h. The reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (0.191 mmol) was added. After stirring at r.t. for 17 h the reaction was quenched by addition of acetic acid (22 μL). The mixture was concentrated in vacuo and purified by column chromatography (CH2Cl2/methanol/water, 3.4:1:0.1 to 2:1:0.1), followed by Dowex 50 (Na+ form) ion exchange column, Sephadex G15 column, microfiltration and lyophilization from dioxane to give C-IV (32.3 mg, 56%) as a colorless foam. For biological testing a small amount was purified by preparative, reversed-phase HPLC to afford the free acid of C-IV as colorless needles.
  • C-IV sodium salt: [α]D 21=−77.9 (c=0.61, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.47-1.89 (m, 25H, CyCH2, nBu, Cy), 0.88 (t, 3J=7.1 Hz, 3H, nBu), 1.31 (d, 3J=6.5 Hz, 3H, Fuc H-6), 2.00 (m, 1H, H-6b), 3.24 (t, 3J=8.9 Hz, 1H, H-2), 3.56-3.60 (m, 2H, Gal H-5, Gal H-3), 3.65 (m, 1H, H-1), 3.72-3.77 (m, 4 H, Gal H-6a, Fuc H-2, Fuc H-4, Lac H-2), 3.80 (dd, 3JG5,G6b=6.9 Hz, 2JG6a,G6b=11.5 Hz, 1H, Gal H-6b), 3.88 (dd, 3JF3,F4=3.3 Hz, 3JF2,F3=10.3 Hz, 1H, Fuc H-3), 3.95 (m, 1H, Gal H-4), 4.68 (d, 3JG1,G2=8.1 Hz, 1H, Gal H-1), 4.85 (m, 1H, Fuc H-5), 4.94 (d, 3JF1,F2=4.0 Hz, 1H, Fuc H-1), 5.41 (dd, 3JG1,G2=8.5 Hz, 3JG2,G3=9.2 Hz, 1H, Gal H-2), 7.48-7.51, 7.60-7.63, 8.07-8.09 (3 m, 5H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 14.48 (nBu), 16.72 (Fuc C-6), 23.27, 23.92, 26.57, 26.82, 27.41, 29.83, 30.04, 31.69, 31.86, 33.06, 34.44, 35.41, 43.54, 44.30 (14C, nBu, Cy, CH2Cy), 63.06 (Gal C-6), 67.70 (Gal C-4), 67.84 (Fuc C-5), 70.21 (Fuc C-2), 71.34 (Fuc C-3), 73.08 (Gal C-2), 73.90 (Fuc C-4), 75.92 (Gal C-5), 80.69 (Lac C-2), 80.41 (C-1), 81.37 (C-2), 83.69 (Gal C-3), 99.91 (Fuc C-1), 100.53 (Gal C-1), 129.60, 130.84, 131.76, 134.23 (6C, C6H5), 166.87 (C═O), 183.26 (COOH); HR-MS (ESI) m/z: calcd for C38H58NaO14[M+H]+: 761.3719. found: 761.3710 (1.2 ppm).
  • C-IV free acid: 1H-NMR (MeOD, 500.1 MHz) δ: 0.54-1.91 (m, 25H, CyCH2, nBu, Cy), 0.89 (t, 3J=7.1 Hz, 3H, nBu), 1.32 (d, 3J=6.6 Hz, 3H, Fuc H-6), 1.98 (m, 1H, H-6b), 3.23 (t, 3J=8.9 Hz, 1H, H-2), 3.56 (m, 1H, Gal H-5), 3.62 (m, 1H, H-1), 3.66 (dd, 3JG3,G4=3.0 Hz, 3JG2,G3=9.8 Hz, 1H, Gal H-3), 3.70-3.75 (m, 3H, Gal H-6a, Fuc H-2, Fuc H-4), 3.79 (dd, 3JG6b,G5=6.9 Hz, 2J6a,G6b=11.3 Hz, 1H, Gal H-6b), 3.85 (dd, 3JF3,F4=3.3 Hz, 3JF2,F3=10.3 Hz, 1H, Fuc H-3), 3.97 (m, 1H, Gal H-4), 4.06 (dd, 3J=2.9, 9.9 Hz, 1H, Lac H-2), 4.67 (d, 3JG1,G2=8.1 Hz, 1H, Gal H-1), 4.88-4.92 (m, 2H, Fuc H-1, Fuc H-5), 5.43 (dd, 3JG1,G2=8.2 Hz, 3JG2,G3=9.6 Hz, 1H, Gal H-2), 7.49-7.52, 7.62-7.64, 8.07-8.09 (3 m, 5H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 14.48 (nBu), 16.74 (Fuc C-6), 23.38, 23.90, 26.54, 26.72, 27.28, 29.83, 29.99, 31.71, 31.81, 33.12, 34.19, 35.07, 42.78, 44.51 (14C, nBu, Cy, CH2Cy), 62.69 (Gal C-6), 67.79 (2C, Fuc C-5, Gal C-4), 70.27 (Fuc C-2), 71.43 (Fuc C-3), 73.10 (Gal C-2), 73.94 (Fuc C-4), 75.90 (Gal C-5), 77.93 (Lac C-2), 80.71 (C-1), 81.45 (C-2), 83.57 (Gal C-3), 100.29 (Fuc C-1), 100.52 (Gal C-1), 129.67, 130.85, 131.63, 134.37 (6C, C6H5), 166.77 (C═O), 178.84 (CO2H).
    • Example 6 {(1R,2R,3R)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-(2-methoxycarbonyl-ethyl)-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (D-III; FIG. 6) [(1R,2R,3R)-1-Hydroxy-3-(2-methoxycarbonyl-ethyl)-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (D-I)
  • A-IV (106 mg, 0.189 mmol) was dissolved in CH2Cl2 (5 mL) and Grubbs cat. 2nd gen. (16.0 mg 18.8 μmol) and methyl acrylate (171 μL, 1.90 mmol) were added. The reaction was heated under reflux for 9 d. After 1 d, 2 d and 7 d additional Grubbs cat. 2nd gen. (each 16.0 mg, 18.8 μmol) and methyl acrylate (each 171 μL, 1.90 mmol) were added. The mixture was concentrated under reduced pressure and purified by column chromatography (petroleum ether/ethyl acetate, 5:1 to 4:1) to yield an E/Z mixture (53.9 mg), which was directly used for hydrogenation. A solution of the E/Z-mixture in THF (4 mL) was added to Pd/C (28.0 mg, 10% Pd) under argon. The mixture was hydrogenated under atmospheric pressure at r.t. After 30 min the reaction was filtered through celite, concentrated under reduced pressure and purified by column chromatography (petroleum ether/ethyl acetate, 3:1 to 2:1) to yield D-I (29.1 mg, 25%) as a brownish oil.
  • [α]D 21=−21.2 (c=1.46, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.94 (m, 1H), 1.14 (d, 3JF6,F5=6.5 Hz, 3H, Fuc H-6), 1.19-1.28 (m, 2H), 1.35-1.47 (m, 2H), 1.67 (m, 1H), 1.74 (m, 1H), 1.99 (m, 1H), 2.29-2.36 (m, 3H), 2.97 (t, 3J=9.2 Hz, 1H, H-2), 3.36 (m, 1H, H-1), 3.57 (s, 3H, Me), 3.67 (m, 1H, Fuc H-4), 3.98 (dd, 3JF3,F4=2.4 Hz, 3JF2,F3=10.2 Hz, 1H, Fuc H-3), 4.09-4.13 (m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.71, 4.76, 4.78, 4.85 (5 m, 5H, CH2Ph), 4.96 (d, 3JF1,F2=3.4 Hz, 1H, Fuc H-1), 4.99 (1 m, 1H, CH2Ph), 7.25-7.41 (m, 15H, 3C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.50 (Fuc C-6), 23.03, 27.48, 30.37, 32.02, 32.33 (5C), 40.72 (C-3), 51.30 (Me), 67.64 (Fuc C-5), 72.97, 73.00 (CH2Ph, C-1), 73.48, 74.82 (2 CH2Ph), 76.01 (Fuc C-2), 77.50 (Fuc C-4), 78.84 (Fuc C-3), 91.25 (C-2), 98.33 (Fuc C-1), 127.43, 127.47, 127.58, 127.62, 127.92, 128.19, 128.28, 128.34, 128.36, 138.23, 138.36, 138.73 (18C, 3 C6H5), 174.33 (COOMe); HR-MS (ESI) m/z: calcd for C37H46NaO8 [M+Na]+: 641.3085. found: 641.3080 (0.8 ppm).
    • {(1R,2R,3R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3-(2-methoxycarbonyl-ethyl)-cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]β-D-galactopyranoside (D-II)
  • According to general procedure C, thioglycoside A-VI (47.9 mg, 61.3 μmol) and glycosyl acceptor D-I (29.1 mg, 47.0 μmol) in dry CH2Cl2 (4 mL) were added via syringe to activated 3 Å molecular sieves (500 mg). A suspension of DMTST (37.6 mg, 146 μmol) and activated 3 Å molecular sieves (250 mg) in CH2Cl2 (2 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 4 h, then the DMTST suspension was added via syringe to the other suspension with some additional CH2Cl2 (1 mL). The reaction was stopped after 65.5 h and work-up according to general procedure C and purification by column chromatography (petroleum ether/ethyl acetate, 4:1 to 3:1) afforded D-II (49.5 mg, 79%) as a colorless foam.
  • [α]D 21=−38.1 (c=0.59, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.45-1.57 (m, 19H, CyCH2, Cy), 1.37 (d, 3J=6.4 Hz, 3H, Fuc H-6), 1.61 (m, 1H, (CH2)2CO2Me), 1.82 (m, 1H, H-6b), 2.13-2.26 (m, 3H, (CH2)2CO2Me), 3.39 (t, 3J=8.1 Hz, 1H, H-2), 3.51 (s, 1H, Fuc H-4), 3.53-3.56 (m, 4H, H-1, Me), 3.84 (dd, 3JG3,G4=3.3 Hz, 3JG2,G3=9.9 Hz, 1H, Gal H-3), 3.93 (m, 1H, Gal H-5), 3.98-4.03 (m, 2H, Fuc H-2, Fuc H-3), 4.13 (dd, 3J=4.5, 8.0 Hz, 1H, Lac H-2), 4.28 (dd, 3JG5,G6a=7.2 Hz, 2JG6a,G6b=11.4 Hz, 1H, Gal H-6a), 4.31 (m, 1H, CH2Ph), 4.38 (dd, 3JG5,G6b=5.6 Hz, 2JG6a,G6b=11.4 Hz, 1H, Gal H-6b), 4.54 (m, 1H, CH2Ph), 4.55 (d, 3JG1,G2=8.0 Hz, 1H, Gal H-1), 4.66-4.71 (m, 3H, CH2Ph, Fuc H-5), 4.73, 4.77 (2 m, 2H, CH2Ph), 5.02 (d, 3JF1,F2=2.3 Hz, 1H, Fuc H-1), 5.05, 5.12 (2 m, 2H, CH2Ph), 5.60 (m, 1H, Gal H-2), 5.85 (m, 1H, Gal H-4), 7.19-7.34, 7.42-7.47, 7.53-7.59, 8.03-8.13 (4 m, 35H, 7 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.78 (Fuc 0-6), 21.18, 25.44, 25.66, 25.70, 26.05, 27.84, 31.26, 32.57, 33.19, 33.38, 40.45 (12C, CyCH2, Cy, (CH2)2CO2Me), 41.94 (C-3), 51.42 (CO2Me), 62.54 (Gal C-6), 66.50 (Fuc C-5), 66.62 (CH2Ph), 70.09 (Gal C-4), 71.48 (Gal C-5), 72.24 (2C, CH2Ph, Gal C-2), 73.79, 74.90 (2 CH2Ph), 76.26 (Fuc C-2), 77.91 (Gal C-3), 78.34, 78.38 (Lac C-2, C-2), 79.09 (Fuc C-4), 79.53 (Fuc C-3), 80.22 (C-1), 97.70 (Fuc C-1) 99.93 (Gal C-1), 126.96, 127.06, 127.23, 127.29, 127.83, 128.04, 128.06, 128.08, 128.15, 128.38, 128.44, 128.48, 128.53, 128.57, 129.62, 129.65, 129.69, 129.74, 129.86, 129.88, 129.94, 129.99, 133.05, 133.19, 133.24, 135.39, 138.64, 138.99, 139.07 (42C, 7 C6H5), 164.55, 166.06, 166.17, 172.45, 174.02 (5C═O); elemental analysis calcd (%) for C80H88O18 (1337.54): C, 71.84; H, 6.63. found: C, 71.70; H, 6.73.
    • {(1R,2R,3R)-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-3-(2-methoxycarbonyl-ethyl)-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (D-III; FIG. 6)
  • D-III (46.0 mg, 34.4 μmol) was hydrogenated with Pd(OH)2/C (25 mg, 10% Pd) in dioxane/H2O (4:1, 3.75 mL) according to general procedure D. After 42 h the mixture was filtered through celite and hydrogenated with fresh Pd(OH)2/C (27 mg) for additional 24 h. The reaction mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (3 mL) and sodium methoxide (51.6 μmol in 55 μl MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched by addition of acetic acid (6 μL). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford D-III (19.2 mg, 73%) as a colorless solid.
  • [α]D 21=−78.3 (c=0.63, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.55-0.75 (m, 4H, CyCH2), 0.84-0.96 (m, 2H, CyCH2, H-4a), 1.04 (m, 1H, H-6a), 1.14 (m, 1H, H-5a), 1.21-1.36 (m, 5H, CyCH2), 1.32 (d, 3J=6.6 Hz, 3H, Fuc H-6), 1.39-1.60 (m, 6H, CyCH2, H-3, H-5b, (CH2)2CO2Me), 1.66 (m, 1H, H-4b), 1.97 (m, 1H, H-6b), 2.18-2.38 (m, 3H, CyCH2, (CH2)2CO2Me), 3.27 (t, 3J=8.4 Hz, 1H, H-2), 3.57 (m, 1H, Gal H-5), 3.63-3.68 (m, 5H, CH3, Gal H-3, H-1), 3.71-3.75 (m, 3H, Gal H-6a, Fuc H-2, Fuc H-4), 3.79 (dd, 3JG5,G6b=6.8 Hz, 2JG6a,G6b=11.3 Hz, 1 H, Gal H-6b), 3.84 (dd, 3JF3,F4=3.3 Hz, 3JF2,F3=10.2 Hz, 1H, Fuc H-3), 3.98 (m, 1H, Gal H-4), 4.07 (dd, 3J=3.0, 9.9 Hz, 1H, Lac H-2), 4.67 (d, 3JG1,G2=8.1 Hz, 1H, Gal H-1), 4.83 (m, 1H, Fuc H-5), 4.92 (m, 1H, Fuc H-1), 5.43 (dd, 3JG1,G2=8.2 Hz, 3JG2,G3=9.6 Hz, 1H, Gal H-2), 7.49-7.52, 7.62-7.65, 8.08-8.09 (3 m, 5H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 16.73 (Fuc C-6), 22.77 (C-5), 26.55, 26.73, 27.28, 27.34 (4C, CyCH2), 29.49 (C-4), 31.34 (C-6), 32.16 ((CH2)2CO2Me), 33.13, 34.20, 35.07 (3C, CyCH2), 42.78 ((CH2)2CO2Me), 43.52 (C-3), 52.03 (Me), 62.62 (Gal C-6), 67.81 (Gal C-4), 67.89 (Fuc C-5), 70.25 (Fuc C-2), 71.41 (Fuc C-3), 73.09 (Gal C-2), 73.90 (Fuc C-4), 75.92 (Gal C-5), 77.98 (Lac C-2), 80.36 (C-1), 80.96 (C-2), 83.50 (Gal C-3), 100.34 (Fuc C-1), 100.50 (Gal C-1), 129.68, 130.85, 131.62, 134.39 (6C, C6H5), 166.77, 176.09, 178.86 (3C═O); elemental analysis calcd (%) for C38H56O16 (768.84)+1½ H2O: C, 57.35; H, 7.47. found: C, 57.57; H, 7.36. HR-MS (ESI) m/z: calcd for C38H56NaO16 [M+Na]+: 791.3461. found: 791.3463 (0.3 ppm).
    • Example 7 {(1R,2R,5R)-5-tert-Butyl-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (E-XI; FIG. 7) rac-(1S,2R,5S)-5-tert-Butyl-2-hydroxycyclohexyl benzoate (rac-E-IV) and rac-(1S,2R,4S)-4-tert-Butyl-2-hydroxycyclohexyl benzoate (rac-E-V)
  • 4-tert-Butylcatechol (E-I) (2.02 g, 12.2 mmol), Rh/Al2O3 (98.9 mg), cyclohexane (4 mL) and THF (0.5 mL) were hydrogenated under 5 bar at r.t. After 24 h the mixture was filtered through celite and evaporated to dryness. The residue was purified by MPLC on silica (CH2Cl2/ethyl acetate, 3:1 to 1:3) to afford a mixture of syn-diols (1.64 g, 78%, rac-E-II:rac-E-III, 1.4:1) as a white solid. The mixture (1.64 g, 9.55 mmol) and dibutyltin oxide (2.37 g, 9.52 mmol) were dissolved in CH2Cl2 (50 mL) and cooled to 0° C. Et3N (2.68 mL, 19.2 mmol) and benzoyl chloride (1.32 mL, 11.45 mmol) were slowly added via syringe. The mixture was warmed to r.t. during 3 h and then quenched with MeOH (2 mL). The solvents were evaporated in vacuo and the crude residue was purified by MPLC on silica (toluene/ethyl acetate, 10:0 to 10:1) affording rac-E-IV (1.15 g, 44%) and rac-E-V (688 mg, 26%) as white solids.
  • rac-E-IV: 1H-NMR (CDCl3, 500.1 MHz) δ: 0.90 (s, 9H, tBu), 1.23 (m, 1H, H-5), 1.42 (m, 1H, H-4a), 1.50-1.57 (m, 2H, H-3a, H-4b), 1.68 (m, 1H, H-6a), 1.85 (m, 1H, H-6b), 2.04 (m, 1H, H-3b), 4.17 (m, 1H, H-2), 5.05 (ddd, 3J=2.7, 4.7, 11.9 Hz, 1H, H-1), 7.44-7.47, 7.56-7.59, 8.05-8.07 (3 m, 5H, C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 19.59 (C-4), 26.42 (C-6), 27.51 (3C, tBu), 30.57 (C-3), 32.49 (tBu), 46.35 (C-5), 67.10 (C-2), 76.47 (C-1), 128.39, 129.58, 130.27, 133.07 (6C, C6H5), 165.62 (C═O); HR-MS (ESI) m/z: calcd for C17H24NaO3 [M+Na]+: 299.1618. found: 299.1621 (1.0 ppm).
  • rac-E-V: 1H-NMR (CDCl3, 500.1 MHz) δ: 0.89 (s, 9H, tBu), 1.18 (m, 1 H, H-5a), 1.34 (m, 1H, H-3a), 1.56 (m, 1H, H-4), 1.83-1.98 (m, 3H, H-5b, H-6), 2.04 (m, 1H, H-3b), 4.25 (m, 1H, H-2), 4.98 (ddd, 3J=2.8, 4.9, 11.7 Hz, 1H, H-1), 7.44-7.47, 7.56-7.59, 8.04-8.06 (3 m, 5H, C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 25.07 (C-5), 25.27 (C-6), 27.48 (3C, tBu), 31.91 (tBu), 31.98 (C-3), 39.43 (C-4), 68.14 (C-2), 75.87 (C-1), 128.39, 129.58, 130.28, 133.06 (6C, C6H5), 165.72 (C═O); HR-MS (ESI) m/z: calcd for C17H24NaO3 [M+Na]+: 299.1618. found: 299.1621 (1.0 ppm).
    • rac-(1R,2R,4R)-2-(Benzoyloxy)-4-tert-butylcyclohexyl 3,5-dinitrobenzoate (rac-E-VI)
  • rac-E-IV (400 mg, 1.45 mmol), triphenylphosphine (1.14 g, 4.33 mmol) and 3,5-dinitrobenzoic acid (921 mg, 4.34 mmol) were dissolved in toluene (25 mL). Diethyl azodicarboxylate (680 μL, 4.32 mmol) was slowly added to the reaction via syringe. The mixture was warmed to 50° C. and stirred for 1 d. The solvent was evaporated in vacuo and the residue, redissolved in a small amount of CH2Cl2, was purified by MPLC on silica (petroleum ether/ethyl acetate, 10:0 to 10:1) affording rac-E-VI (428 mg, 63%) and recovered starting material rac-E-IV (103 mg, 26%) as white solids.
  • 1H-NMR (CDCl3, 500.1 MHz) δ: 0.93 (s, 9H, tBu), 1.25-1.47 (m, 3H, H-3., H-4, H-5a), 1.68 (m, 1H, H-6a), 1.94 (m, 1H, H-5b), 2.29-2.35 (m, 2H, H-3b, H-6b), 5.27 (ddd, 3J=4.9, 9.7, 11.4 Hz, 1H, H-1), 5.35 (ddd, 3J=4.7, 9.9, 10.5 Hz, 1H, H-2), 7.36-7.39, 7.48-7.52, 7.96-7.98 (3 m, 5H, C6H5), 9.06, 9.14-9.15 (2 m, 3 H, C6H3); 13C-NMR (CDCl3, 125.8 MHz) δ: 24.79 (C-5), 27.52 (3C, tBu), 29.76 (C-6), 31.79 (C-3), 32.36 (tBu), 45.73 (C-4), 74.80 (C-2), 77.55 (C-1), 122.31, 128.39, 129.44, 129.58, 129.74, 133.17, 133.81, 148.54 (12C, C6H5, C6H3), 162.16, 165.89 (2C═O); HR-MS (ESI) m/z: calcd for C24H26N2NaO8 [M+Na]+: 493.1581. found: 493.1582 (0.2 ppm).
    • rac-(1R,2R,5R)-5-tert-Butyl-2-hydroxycyclohexyl benzoate (rac-E-VII)
  • rac-E-VI (135 mg, 0.287 mmol) was suspended in MeOH (5 mL). Et3N (1 mL) was added and the reaction stirred for 1 h. The solvents were evaporated in vacuo and the residue was purified by MPLC on silica (toluene/ethyl acetate, 6:0 to 6:1) affording rac-E-VII (63.2 mg, 80%) as a white solid.
  • 1H-NMR (CDCl3, 500.1 MHz) δ: 0.88 (s, 9H, tBu), 1.12 (m, 1H, H-4a), 1.19-1.32 (m, 2H, H-5, H-6a), 1.41 (m, 1H, H-3a), 1.80 (m, 1H, H-4b, 2.12-2.18 (m, 2H, H-3b, H-6b), 3.69 (ddd, 3J=4.9, 9.3, 11.3 Hz, 1H, H-2), 4.88 (ddd, 3J=4.7, 9.4, 10.7 Hz, 1H, H-1), 7.43-7.46, 7.55-7.58, 8.06-8.07 (3 m, 5H, C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 24.89 (C-4), 27.54 (3C, tBu), 31.44 (C-6), 32.28 (tBu), 32.61 (C-3), 46.01 (C-5), 73.33 (C-2), 79.47 (C-1), 128.34, 129.64, 130.23, 133.05 (6C, C6H5), 166.82 (C═O); HR-MS (ESI) m/z: calcd for C17H24NaO3 [M+Na]+: 299.1618. found: 299.1619 (0.3 ppm).
    • [(1R,2R,5R)-5-tert-Butyl-1-hydroxy-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-α— and β-L-galactopyranoside (E-VIII) and [(1S,2S,5S)-5-tert-Butyl-1-hydroxy-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (E-IX)
  • A mixture of rac-E-VII (76.9 mg, 0.278 mmol), A-VI (202 mg, 0.421 mmol), Bu4NBr (274 mg, 0.850 mmol) and powdered 4 Å molecular sieves (1 g) in CH2Cl2 (4 mL) and DMF (1 mL) was stirred at r.t. under argon for 3.5 h. Then, CuBr2 (188 mg, 0.844 mmol) was added and the reaction mixture was stirred at r.t. for 11 h. The reaction mixture was filtered through celite and the filtrate was diluted with CH2Cl2 (30 mL). The organic layer was successively washed with satd. aqueous NaHCO3 and brine (each 30 mL) and the aqueous layers were extracted with CH2Cl2 (3×40 mL). The combined organic layers were dried with Na2SO4, filtered and co-evaporated with toluene to dryness. The residue was purified by MPLC on silica (petroleum ether/CH2Cl2/diethyl ether, 2:1:0 to 2:1:1) to afford the fucosylated diastereomers. To a stirred solution of these diastereomers in methanol/water (5:1, 6 mL), lithium hydroxide (200 mg) was added and the mixture warmed to 50° C. After stirring for 4 h the reaction mixture was diluted with CH2Cl2 (30 mL) and the organic layer was washed with brine (50 mL). The aqueous layer was extracted with CH2Cl2 (3×30 mL), and the combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo. The residue was purified by MPLC on silica (petroleum ether/ethyl acetate, 4:0 to 4:1) to yield E-VIII (72.1 mg, 44%, α:β=1:0.12, yield over two steps) as an anomeric mixture and E-IX (63.0 mg, 38%, yield over two steps) as pure α-anomer.
  • αE-VIII: [α]D 21=−41.3 (c=0.31, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.86 (s, 9H, tBu), 0.97-1.38 (m, 7H, Fuc H-6, H-3a, H-4a, H-5, H-6a), 1.74 (m, 1H, H-4b), 1.99-2.06 (m, 2H, H-3b, H-6b), 3.22 (m, 1H, H-2), 3.47 (m, 1H, H-1), 3.70 (m, 1H, Fuc H-4), 3.94 (dd, 3JF3,F4=2.4 Hz, 3JF2,F3=10.1 Hz, 1H, Fuc H-3), 4.05-4.09 (m, 2H, Fuc H-2, Fuc H-5), 4.65, 4.66, 4.75, 4.82, 4.87 (5 m, 5H, CH2Ph), 4.97-5.00 (m, 2H, Fuc H-1, CH2Ph), 7.26-7.41 (m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.65 (Fuc C-6), 25.17 (C-4), 27.55 (3C, tBu), 29.54 (C-3), 32.19 (tBu), 33.63 (C-6), 45.82 (C-5), 66.97 (Fuc C-5), 73.15, 73.33 (2 CH2Ph), 73.52 (C-1), 74.86 (CH2Ph), 76.16 (Fuc C-2), 77.41 (Fuc C-4), 79.21 (Fuc C-3), 84.09 (C-2), 96.33 (Fuc C-1), 127.40, 127.48, 127.64, 127.69, 127.90, 128.21, 128.35, 128.44, 138.41, 138.50, 138.81 (18C, 3 C6H5); HR-MS (ESI) m/z: calcd for C37H48NaO6 [M+Na]+: 611.3343. found: 611.3346 (0.5 ppm).
  • E-IX: [α]D 21=−40.7 (c=0.38, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.85 (s, 9H, tBu), 1.01-1.17 (m, 6H, Fuc H-6, H-4a, H-5, H-6a), 1.29 (m, 1H, H-3a), 1.70 (m, 1H, H-4b), 1.97-2.04 (m, 2H, H-3b, H-6b), 3.17 (m, 1H, H-2), 3.45 (m, 1H, H-1), 3.69 (m, 1H, Fuc H-4), 3.96-4.05 (m, 3H, Fuc H-2, Fuc H-3, Fuc H-5), 4.66, 4.73, 4.76, 4.81, 4.87, 4.97 (6 m, 6H, CH2Ph), 4.98 (m, 1H, Fuc H-1), 7.26-7.41 (m, 15H, 3 C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.69 (Fuc C-6), 25.32 (C-4), 27.58 (3C, tBu), 31.26 (C-3), 32.25 (tBu), 32.88 (C-6), 45.78 (C-5), 66.57 (Fuc C-5), 72.63, 74.19 (2 CH2Ph), 74.66 (C-1), 74.80 (CH2Ph), 76.33 (Fuc C-2), 77.40 (Fuc C-4), 80.01 (Fuc C-3), 87.22 (C-2), 101.01 (Fuc C-1), 127.34, 127.52, 127.58, 127.84, 128.18, 128.22, 128.34, 128.39, 128.47, 137.95, 138.53, 138.65 (18C, 3 C6H5).
    • {(1R,2R,5R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-5-tert-butyl-cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-β-D-galactopyranoside (E-X)
  • According to general procedure C, thioglycoside A-VI (125 mg, 0.161 mmol) and glycosyl acceptor E-VIII (71.4 mg, 0.121 mmol) in dry CH2Cl2 (4 mL) were added via syringe to activated 4 Å molecular sieves (1 g). A suspension of DMTST (120 mg, 0.465 mmol) and activated 4 Å molecular sieves (500 mg) in CH2Cl2 (2 mL) was prepared in a second flask. Both suspensions were stirred at r.t. for 2 h, before adding the DMTST suspension via syringe to the other suspension with some additional CH2Cl2 (1 mL). The reaction was stopped after 45 h and worked-up according to general procedure C. The crude product was purified by MPLC on silica (toluene/ethyl acetate, 11.5:0 to 11.5:1) to yield E-X (107 mg, 68%) as a colorless foam.
  • [α]D 21−57.9 (c=0.50, CHCl3); 1H-NMR (CDCl3, 500.1 MHz) δ: 0.46-1.43 (3 m, 17H, CyCH2, Cy), 0.58 (s, 9H, tBu), 1.36 (d, 3J=6.0 Hz, 3H, Fuc H-6), 1.60 (m, 1H, H-4b), 1.81 (m, 1H, H-6b), 1.99 (m, 1H, H-3b), 3.45 (m, 1H, H-2), 3.55 (m, 1H, H-1), 3.58 (s, 1H, Fuc H-4), 3.87-3.90 (m, 2H, Gal H-3, Gal H-5), 3.97-4.04 (m, 2H, Fuc H-2, Fuc H-3), 4.16 (m, 1H, Lac H-2), 4.29 (m, 2H, Gal H-6), 4.39 (m, 1H, CH2Ph), 4.55-4.57 (m, 2H, Gal H-1, CH2Ph), 4.63 (m, 1H, CH2Ph), 4.69-4.74 (m, 2H, CH2Ph), 4.79-4.83 (m, 2H, Fuc H-5, CH2Ph), 4.88 (d, 3JF1,F2=2.1 Hz, 1H, Fuc H-1), 5.04, 5.13 (2 m, 2H, CH2Ph), 5.56 (m, 1H, Gal H-2), 5.91 (m, 1H, Gal H-4), 7.17-7.35, 7.39-7.48, 7.54-7.55, 8.04-8.11 (m, 35H, 7C6H5); 13C-NMR (CDCl3, 125.8 MHz) δ: 16.62 (Fuc C-6), 24.43 (C-4), 25.40, 25.71, 26.06 (3C, CyCH2), 27.19 (3C, tBu), 28.97 (C-3), 31.95 (tBu), 32.23 (C-6), 32.49, 33.17, 33.44 (3C, CyCH2), 40.44 (CyCH2), 45.50 (C-5), 62.21 (Gal C-6), 65.98 (Fuc C-5), 66.58 (CH2Ph), 69.86 (Gal C-4), 71.19 (Gal C-5), 72.53, 72.56 (Gal C-2, CH2Ph), 73.02 (CH2Ph), 74.90 (CH2Ph), 75.25 (C-2), 76.44 (Fuc C-2), 77.51 (Gal C-3), 78.08 (Lac C-2), 79.24 (Fuc C-4), 79.64 (Fuc C-3), 81.37 (C-1), 94.16 (Fuc C-1), 100.24 (Gal C-1), 126.87, 126.95, 127.22, 127.38, 127.93, 127.95, 128.03, 128.15, 128.34, 128.42, 128.47, 128.50, 129.64, 129.74, 129.83, 129.88, 129.91, 133.04, 133.16, 133.21, 135.43, 138.86, 139.08, 139.14 (42C, 7 C6H5), 164.56, 165.65, 166.11, 172.47 (4C═O); elemental analysis calcd (%) for C80H90O16 (1307.56): C, 73.48; H, 6.94. found: C, 73.50; H, 6.95.
    • {(1R,2R,5R)-5-tert-Butyl-2-[(6-deoxy-α-L-galactopyranosyl)oxy]-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (E-XI; FIG. 7)
  • A mixture of E-X (102 mg, 77.9 μmol), Pd(OH)2/C (49.4 mg), dioxane (3 mL) and water (0.75 mL) was hydrogenated under 4 bar at r.t. After 37 h TLC control indicated completion of the reaction and the mixture was filtered through celite and evaporated to dryness. The residue was redissolved in methanol (5 mL) and sodium methoxide (0.195 mmol in 255 μL MeOH) was added. After stirring at r.t. for 14 h the reaction was quenched by addition of acetic acid (23 μL). The mixture was concentrated in vacuo and purified by preparative, reversed-phase HPLC to afford compound E-XI (50.9 mg, 88%) as a white solid.
  • [α]D 21=−93.2 (c=0.91, MeOH); 1H-NMR (MeOD, 500.1 MHz) δ: 0.60-0.77 (m, 5H, H-6a, CyCH2), 0.65 (s, 9H, tBu), 0.84 (m, 1H, H-4a), 0.93 (m, 1 H, CyCH2), 1.01 (m, 1H, H-5), 1.15 (m, 1H, H-3a), 1.26 (d, 3JF5,F6=6.6 Hz, 3H, Fuc H-6), 1.29-1.39 (m, 5H, CyCH2), 1.43 (m, 1H, CyCH2), 1.53 (m, 1H, CyCH2), 1.60-1.66 (m, 2H, H-4b, CyCH2), 1.95 (m, 1H, H-6b), 2.05 (m, 1H, H-3b), 3.33 (m, 1H, H-2), 3.56-3.61 (m, 2H, H-1, Gal H-5), 3.69-3.74 (m, 4H, Fuc H-2, Fuc H-4, Gal H-3, Gal H-6a), 3.79 (m, 3JG6b,G5=6.9 Hz, 2JG6a,G6b=11.3 Hz, 1H, Gal H-6b), 3.91 (dd, 3JF3,F4=3.4 Hz, 3JF2,F3=10.1 Hz, 1H, Fuc H-3), 4.00 (m, 1H, Gal H-4), 4.10 (dd, 3J=2.9, 10.0 Hz, 1H, Lac H-2), 4.67 (d, 3JG1,G2=8.0 Hz, 1H, Gal H-1), 4.77 (m, 1H, Fuc H-5), 4.82 (d, 3JF1,F2=3.8 Hz, 1H, Fuc H-1), 5.36 (dd, 3JG1,G2=8.0 Hz, 3JG2,G3=9.8 Hz, 1H, Gal H-2), 7.49-7.52 (m, 2H, C6H5), 7.61-7.64 (m, 1H, C6H5), 8.10-8.12 (m, 2H, C6H5); 13C-NMR (MeOD, 125.8 MHz) δ: 16.53 (Fuc C-6), 25.74 (C-4), 26.60, 26.82, 27.30 (3C, CyCH2), 27.78 (3C, tBu), 29.73 (C-3), 32.83 (tBu), 33.11 (CyCH2), 33.74 (C-6), 34.26 (Lac C-4), 35.12 (CyCH2), 42.76 (Lac C-3), 47.02 (C-5), 62.69 (Gal C-6), 67.38 (Fuc C-5), 67.99 (Gal C-4), 70.03 (Fuc C-2), 71.57 (Fuc C-3), 73.63 (Gal C-2), 73.96 (Fuc C-4), 76.02 (Gal C-5), 76.90 (C-2), 78.03 (Lac C-2), 81.57 (C-1), 83.17 (Gal C-3), 96.51 (Fuc C-1), 101.13 (Gal C-1), 129.74, 130.90, 131.70, 134.40 (6C, C6H5), 166.83 (C═O), 178.78 (COOH); HR-MS (ESI) m/z: calcd for C38H58NaO14 [M+H]+: 761.3719. found: 761.3723 (0.5 ppm).
    • Example 8 {(1R,2R,3S,5R)-2-[(deoxy-α-L-galactopyranosyl)oxy]-3,5-dimethyl-cyclohex-1-yl}2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside sodium salt (F-VI; FIG. 8) [(1R,2R,3S,5R)-1-tert-Butyldimethylsilyloxy-5-hydroxymethyl-3-methyl-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (F-I)
  • To a solution of X (137 mg, 0.191 mmol) in dry THF (2 mL) was added a solution of 1M LiAlH4 (667 μL, 0.667 mmol) in THF at 0° C. under argon over a period of 10 min. After 1 h the reaction was quenched with satd. aqueous (NH4)2SO4 (0.5 mL) and stirred at r.t. for 1 h. Then the mixture was dried with Na2SO4, filtered and the solvent evaporated in vacuo. Column chromatography (petroleum ether/ethyl acetate, 6:1) of the residue gave F-I (110 mg, 84%).
  • [α]D 20=−51.3 (c=0.335, CHCl3); ESI-MS m/z: calcd for C41H58NaO7Si [M+Na]+: 713.38. found: 713.35.
    • [(1R,2R,3S,5R)-1-tert-Butyldimethylsilyloxy-5-chloromethyl-3-methyl-cyclohex-2-yl]2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (F-II)
  • To a solution of F-I (105 mg, 0.152 mmol) in dry DCE (1.5 mL) under argon 1-chloro-N,N,2-trimethylpropenylamine (43 μL, 0.304 mmol) was added dropwise. After stirring for 45 min at r.t. the reaction was quenched with MeOH/25% aqueous NH3 (1:1, 0.5 mL) and evaporated to dryness. Column chromatography (petroleum ether/ethyl acetate, 19:1) of the residue yielded F-II (91 mg, 85%).
  • [α]D 20=−46.3 (c=2.20, CHCl3); ESI-MS m/z: calcd. for C41H57ClNaO6Si [M+Na]+: 731.34. found 731.42.
    • [(1R,2R,3S,5R)-1-tert-Butyldimethylsilyloxy-3,5-dimethyl-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (F-III)
  • To a solution of F-II (89 mg, 0.125 mmol) and AIBN (21 mg, 0.127 mmol) in dry THF (1.5 mL) was added freshly distilled Bu3SnH (366 μL, 1.38 mmol) via a syringe under argon. After stirring for 90 min at 90° C. the mixture was cooled to r.t. and diluted in MeCN (5 mL). The solution was washed with hexane (5 mL) and the layers were separated. The hexane layer was washed with MeCN (2×5 mL). The combined MeCN layers were evaporated in vacuo and the residue purified by column chromatography (petroleum ether+4% ethyl acetate) to yield F-III (60 mg, 71%).
  • [α]D 20=−43.6 (c=1.28, CHCl3); ESI-MS m/z: calcd. for C41H58NaO6Si [M+Na]+: 697.97. found 697.47.
    • [(1R,2R,3S,5R)-1-Hydroxy-3,5-dimethyl-cyclohex-2-yl] 2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranoside (F-IV)
  • A mixture of F-III (70 mg, 0.104 mmol), THF (1.5 mL), AcOH (1.8 mL) and H2O (1.5 mL) was stirred for 4 h at 80° C. The mixture was cooled to r.t., neutralized with satd. aqueous NaHCO3 (approx. 14 mL), diluted with DCM (15 mL) and washed with water (15 mL). The aqueous layer was then extracted with DCM (2×10 mL). The combined organic layers were dried with Na2SO4, filtered and evaporated to dryness. Column chromatography (petroleum ether/ethyl acetate, 8:1) of the crude product gave F-IV (40 mg, 68%).
  • [α]D 20=−40.8 (c=2.00, CHCl3); ESI-MS m/z: calcd. for C35H44NaO6 [M+Na]+: 583.30. found 583.18.
    • {(1R,2R,3S,5R)-2-[(2,3,4-tris-O-benzyl-6-deoxy-α-L-galactopyranosyl)oxy]-3,5-dimethyl-cyclohex-1-yl} 2,4,6-tri-O-benzoyl-3-O-[(1S)-1-benzyloxycarbonyl-2-cyclohexyl-ethyl]-β-D-galactopyranoside (F-V)
  • A mixture of F-IV (45 mg, 80.3 μmol), A-VI (85 mg, 108 μmol) and activated powdered molecular sieves 4 Å (1 g) in DCM (2 mL) was stirred at r.t. under argon for 4 h. Then a pre-stirred mixture (4 h, r.t.) of DMTST (83 mg, 0.321 mmol) and activated powered molecular sieves 4 Å (200 mg) in dry DCM (2 mL) was added. After 24 h the reaction mixture was filtered over Celite and the filtrate was diluted with DCM (10 mL). The organic layer was washed with satd. aqueous NaHCO3 and brine (each 5 mL) and the aqueous layers were extracted with DCM (2×5 ml). The combined organic layers were dried with Na2SO4, filtered and evaporated to dryness. The residue was purified by column chromatography on silica gel (petroleum ether/ethyl acetate, 6:1) to yield F-V (63 mg, 62%).
  • [α]D 20=−47.0 (c=2.17, CHCl3); ESI-MS m/z: calcd. for C78H86NaO16 [M+Na]+: 1301.58. found 1301.64.
    • {(1R,2R,3S,5R)-2-[(deoxy-α-L-galactopyranosyl)oxy]-3,5-dimethyl-cyclohex-1-yl} 2-O-benzoyl-3-O-[(1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside sodium salt (F-VI; FIG. 8)
  • A mixture of F-V (50 mg, 39.1 μmol), Pd(OH)2/C (27 mg, 10% Pd), dioxane (1.5 mL) and water (400 μL) was hydrogenated in a Parr-shaker at 5 bar. After 4 h the mixture was filtered over Celite and evaporated to dryness. The residue was re-dissolved in MeOH (3 mL) and NaOMe (97.8 μmol in 160 μL MeOH) was added. After stirring at r.t. for 16 h the reaction was quenched with AcOH (10 μL), concentrated in vacuo and purified by preparative, reversed-phase HPLC. The freeze-dried product was re-dissolved in water and one equivalent of NaOH was added. The solution was lyophilized from water to afford F-VI (23.3 mg, 80%) as a white solid.
  • [α]D 20=−89.0 (c=1.16, H2O); ESI-MS m/z: calcd. for C36H54NaO14 [M+H]+: 733.34. found 733.41.
    • Example 9 Synthesis of compound G-IV (FIG. 12)
  • Synthesis of intermediate G-II: Compound XXII (100 mg; Example 2) was treated with 0.01N NaOEt in EtOH (2 ml) 2 h at room temperature, neutralized with AcOH and the solution was evaporated to dryness. The residue was purified by column chromatography to give G-II (47 mg).
  • Synthesis of intermediate G-III: Compound G-II (250 mg) was dissolved in dioxane-water (10:1, 6.6 ml) and treated with 10% Pd/C under atmosphere of hydrogen for overnight. Solid was filtered off and filtrate was evaporated to dryness. The residue was purified by column chromatography (silica gel) to give compound G-III (100 mg).
  • Synthesis of compound G-IV: NH2OH. HCl (64 mg) was dissolved in H2O (0.5 ml). To this solution was added a solution of NaOH (70 mg) in H2O (0.5 ml). Compound G-III (25 mg) in MeOH (0.5 ml) was added to the above solution with stirring at room temperature. The mixture was stirred at room temperature for 15 min and then neutralized to pH 7.0 by adding 1N HCl solution. Solvent was evaporated off and the residue was purified by column chromatography (silica gel) to give compound G-IV.
    • Example 10 Synthesis of Compound H-IV (FIG. 13)
  • Synthesis of intermediate H-II: Compound F-V (100 mg; Example 8) was treated with 0.01N NaOEt in EtOH (2 ml) 2 h at room temperature, neutralized with AcOH and the solution was evaporated to dryness. The residue was purified by column chromatography to give H-II (55 mg).
  • Synthesis of intermediate H-III: Compound H-II (125 mg) was dissolved in dioxane-water (10:1, 6.6 ml) and treated with 10% Pd/C under atmosphere of hydrogen for overnight. Solid was filtered off and filtrate was evaporated to dryness. The residue was purified by column chromatography (silica gel) to give compound H-III (75 mg).
  • Synthesis of compound H-IV: Compound H-III is treated in the same way as described for the synthesis of G-IV to give H-IV.
    • Example 11 Synthesis of Pegylated Mimic (FIG. 10) Synthesis of Second Compound of FIG. 10
  • First compound (100 mg) of FIG. 10 was mixed with ethylenediamine under the argon. The resulting mixture was heated at 70° C. for 7 hr. After evaporation, the residue was purified on C-18 column to afford 55 mg second compound. Yield 68%
    • PEGylation of Second Compound of FIG. 10
  • Second compound (5 mg) was mixed with mPEG-nitrophenylcarbonate (5K) 75 mg, triethylamine 5 ul in DMF (2 mL). The resulting mixture was stirred at rt for 3 h. The solvent was removed at reduced pressure. The residue was purified on C-18 to afford 40 mg product.
    • Example 12 Synthesis of Tetramer Pegylated Mimic (FIG. 11)
  • Second compound (20 mg) from Example 11 was mixed with 200 mg 4-arm PEG glutamidylsuccinate, triethylamine 5 ul and DMF 2 mL. The resulting mixture was stirred at it for 2 hr. After removing the solvent, the residue was purified on HPLC to afford the product.
    • Example 13 E-Selectin Assay
  • E-selectin Protocol: The inhibition assay to screen glycomimetic antagonists of E-selectin is a competitive binding assay, which allows the determination of IC50 values. Briefly, E-selectin/Ig chimera is immobilized by incubation at 37° C. in 96 well microtiter plates for 2 hours. To reduce nonspecific binding, bovine serum albumin is added to each well and incubated at room temperature for 2 hours. The plate is washed and serial dilutions of the test compounds are added to the wells in the presence of conjugates of biotinylated, sLea polyacrylamide with streptavidin/horseradishperoxidase and incubated for 2 hours at room temperature. To determine the amount of sLea bound to immobilized E-selectin after washing, the peroxidase substrate, 3,31,5,51 tetramethylbenzidin (TMB) is added. After 3 minutes, the enzyme reaction is stopped by the addition of H3PO4 and the absorbance of light at a wavelength of 450 nm is determined. The concentration of test compound required to inhibit binding by 50% is determined and reported as the IC50 value for each glycomimetic E-selectin antagonist. In addition to reporting the absolute IC50 value as measured above, relative IC50 values are determined by a ratio of the IC50 measured for the test compound to that of a glycomimetic internal control (reference) for each assay. The results from the testing in this assay of several of the compounds disclosed herein are shown below.
  • Compounds IC50 (μM) rIC50
    #1 15.5 0.076
    #2 10.1 0.049
    #3 3.75 0.027
  • All of the above U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet, are incorporated herein by reference, in their entirety.
  • From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

Claims (12)

1.-3. (canceled)
4. A compound comprising:
Figure US20110257380A1-20111020-C00080
R1═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; C(═O)OX, alkanyl substituted with C(═O)OX, C(═O)NHX, alkanyl substituted with C(═O)NHX, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; NHX, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH;
R2═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, OH, or NHX where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)OX where X is C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; —C(═O)NH(CH2)nNH2 where n=0-30, C(═O)NHX or CX2OH, where X═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; OX, NHX, NH(═O)X, where X═H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl or heteroaryl either of which may be substituted with one or more of Me, OMe, halide, or OH; with the proviso that R1 and R2 are not both H;
R3═—OH,
Figure US20110257380A1-20111020-C00081
 —O—C(═O)—X, —NH2, —NH—C(═O)—NHX, or —NH—C(═O)—X where n=0-2 and X is independently selected from C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl,
Figure US20110257380A1-20111020-C00082
 where Q is H or a physiologically acceptable cation, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, and where n=0-10, and any of the above ring compounds may be substituted with one to three independently selected of Cl, F, CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, C1-C14 aryl, or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, or C1-C14 aryl;
Figure US20110257380A1-20111020-C00083
 where R9 is aryl, heteroaryl, cyclohexane, t-butane, adamantane, or triazole, and any of R9 may be substituted with one to three independently selected of Cl, F CF3, C1-C8 alkoxy, NO2, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8alkynyl or OY, C(═O)OY, NY2 or C(═O)NHY where Y is H, C1-C8 alkanyl, C1-C8 alkenyl, and C1-C8 alkynyl or C1-C14 aryl; and where R10 is one of
Figure US20110257380A1-20111020-C00084
 where Q is H or a physiologically acceptable cation, C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, aryl, heteroaryl, (CH2)m-aryl or (CH2)m-heteroaryl where m is 1-10, n=1-4, Z and Y═C1-C8 alkanyl, C1-C8 alkenyl, C1-C8 alkynyl, halogenated C1-C8 alkanyl, aryl and heteroaryl substituted with Me, OMe, halide, OH; and
R5═H, D-mannose, L-galactose, D-arabinose, L-fucose, polyols.
5. A compound consisting of the compound of claim 4.
6.-17. (canceled)
18. The compound according to claim 5 having the formula:
Figure US20110257380A1-20111020-C00085
where Me is methyl, Et is ethyl and Bz is benzoyl.
19. The compound according to claim 5 having the formula:
Figure US20110257380A1-20111020-C00086
where Me is methyl and Bz is benzoyl.
20. The compound according to claim 5 having the formula:
Figure US20110257380A1-20111020-C00087
where Me is methyl, Et is ethyl and Bz is benzoyl.
21. The compound according to claim 5 having the formula:
Figure US20110257380A1-20111020-C00088
where Me is methyl and Bz is benzoyl.
22. The compound according to claim 4 with polyethylene glycol attached thereto.
23. The compound according to claim 4 attached to another of the compound according to claim 4 by polyethylene glycol.
24. The compound according to claim 5 with polyethylene glycol attached thereto.
25. The compound according to claim 5 attached to another of the compound according to claim 5 by polyethylene glycol.
US13/093,611 2006-10-12 2011-04-25 Glycomimetic replacements for hexoses and n-acetyl hexosamines Abandoned US20110257380A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/093,611 US20110257380A1 (en) 2006-10-12 2011-04-25 Glycomimetic replacements for hexoses and n-acetyl hexosamines

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85146706P 2006-10-12 2006-10-12
US11/973,891 US7964569B2 (en) 2006-10-12 2007-10-09 Glycomimetic replacements for hexoses and N-acetyl hexosamines
US13/093,611 US20110257380A1 (en) 2006-10-12 2011-04-25 Glycomimetic replacements for hexoses and n-acetyl hexosamines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/973,891 Continuation US7964569B2 (en) 2006-10-12 2007-10-09 Glycomimetic replacements for hexoses and N-acetyl hexosamines

Publications (1)

Publication Number Publication Date
US20110257380A1 true US20110257380A1 (en) 2011-10-20

Family

ID=39402172

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/973,891 Active 2029-10-18 US7964569B2 (en) 2006-10-12 2007-10-09 Glycomimetic replacements for hexoses and N-acetyl hexosamines
US13/093,611 Abandoned US20110257380A1 (en) 2006-10-12 2011-04-25 Glycomimetic replacements for hexoses and n-acetyl hexosamines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/973,891 Active 2029-10-18 US7964569B2 (en) 2006-10-12 2007-10-09 Glycomimetic replacements for hexoses and N-acetyl hexosamines

Country Status (5)

Country Link
US (2) US7964569B2 (en)
EP (1) EP2074132B1 (en)
JP (2) JP5298020B2 (en)
CA (1) CA2666103C (en)
WO (1) WO2008060378A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014149837A1 (en) * 2013-03-15 2014-09-25 Glycomimetics, Inc. Compounds and methods to enhance the oral availability of glycomimetics
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
US10519181B2 (en) 2014-12-03 2019-12-31 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
US11045485B2 (en) * 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US11707474B2 (en) 2018-03-05 2023-07-25 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486497B2 (en) 2007-12-10 2016-11-08 The University Of Queensland Treatment of immunocompromised conditions
CA2760292A1 (en) 2009-05-01 2010-11-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
JPWO2011040574A1 (en) * 2009-09-30 2013-02-28 国立大学法人京都大学 Method for producing azetidinylmethoxypyridine derivative and use thereof
WO2012037034A1 (en) * 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2012061662A1 (en) 2010-11-03 2012-05-10 Glycomimetics, Inc. Glycomimetic-peptidomimetic inhibitors of e-selectins and cxcr4 chemokine receptors
WO2015109049A1 (en) * 2014-01-17 2015-07-23 Glycomimetics, Inc. E-selectin antagonists modified by macrocycle formation to the galactose
KR20220012246A (en) 2019-04-24 2022-02-03 글리코미메틱스, 인크. E-selectin, galectin-3, and/or galactose-linked multimeric glycomimetic inhibitors of CXCR4 chemokine receptors

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4471057A (en) * 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
DK17885D0 (en) * 1985-01-14 1985-01-14 Karlsson Karl Anders ANTIVIRAL AGENT
US4876199A (en) * 1985-04-04 1989-10-24 Fred Hutchinson Cancer Research Center Hybridomas producing monoclonal antibodies to mono-, di-, and trifucosylated type 2 chain
US4851511A (en) * 1986-01-30 1989-07-25 Fred Hutchinson Cancer Research Center Monoclonal antibody that specifically binds to disialosyl Lea
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
ES2058070T3 (en) * 1986-05-09 1994-11-01 Pulverer Gerhard USE OF SPECIFIC MONOSACCHARIDES FOR THE PREPARATION OF A MEDICINAL PRODUCT TO PREVENT METASTASIS OF MALIGNANT TUMORS.
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US6033665A (en) 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US6387884B1 (en) 1990-06-18 2002-05-14 Stanford University Leukocyte homing modulation
US6391857B1 (en) 1990-06-18 2002-05-21 Stanford University Methods and compositions for endothelial binding
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5648344A (en) 1990-07-30 1997-07-15 Glycomed Incorporated Methods of treating inflammation using selection binding compounds
US5143712A (en) * 1990-07-30 1992-09-01 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5789573A (en) 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JPH06504619A (en) 1990-11-23 1994-05-26 ザ ジェネラル ホスピタル コーポレーション Inhibition of cell adhesion protein-carbohydrate interactions
US5151360A (en) * 1990-12-31 1992-09-29 Biomembrane Institute Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US6121233A (en) 1991-04-19 2000-09-19 John L. Magnani Methods for the inhibition of cancer metastasis mediated by endothelial adhesion molecules
ES2201049T3 (en) 1991-05-06 2004-03-16 Genentech, Inc. A BINDING OF SELECTINE.
US5318890A (en) 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US5646123A (en) 1991-06-10 1997-07-08 Alberta Research Council Time dependent administration of oligosaccharide glycosides related to blood group determinants having a type I or type II core structure in reducing inflammation in a sensitized mammal arising form exposure to an antigen
US5580858A (en) 1991-06-10 1996-12-03 Alberta Research Council Immunosuppressive and tolerogenic modified Lewisx compounds
US5352670A (en) 1991-06-10 1994-10-04 Alberta Research Council Methods for the enzymatic synthesis of alpha-sialylated oligosaccharide glycosides
CA2118695A1 (en) 1991-09-10 1993-03-18 George A. Heavner Peptide inhibitors of inflammation mediated by selectins
US5268364A (en) * 1991-12-12 1993-12-07 The Biomembrane Institute Method for inhibiting selectin-dependent adhesion of leukocytes and platelets by O-glycosylation modification
AU3914393A (en) 1991-12-18 1994-03-15 Board Of Regents Of The University Of Oklahoma, The Peptide inhibitors of inflammation mediated by selectins
US5591835A (en) 1992-06-29 1997-01-07 Glycomed Incorporated Substituted lactose derivatives
CA2100412A1 (en) 1992-07-15 1994-01-16 Yutaka Yamada Glycolipid derivatives
JPH08503694A (en) 1992-09-08 1996-04-23 セントコー・インコーポレーテッド Peptide-based cell adhesion inhibitor
US5519008A (en) 1992-09-10 1996-05-21 Glycomed Incorporated Derivatives of triterpenoid acids as inhibitors of cell-adhesion molecules ELAM-1 (E-selectin) and LECAM-1 (L-selectin)
WO1994006442A1 (en) 1992-09-11 1994-03-31 The Regents Of The University Of California Sulfated ligands for l-selectins and use of chlorates and or sulfatases for the treatment of inflammation
US5695752A (en) 1992-09-11 1997-12-09 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
EP0601417A3 (en) 1992-12-11 1998-07-01 Hoechst Aktiengesellschaft Physiologically compatible and degradable polymer-based carbohydrate receptor blockers, a method for their preparation and their use
US5710123A (en) 1992-12-18 1998-01-20 Centocor, Inc. Peptide inhibitors of selectin binding
JP3887011B2 (en) 1992-12-29 2007-02-28 ジェネンテク，インコーポレイテッド Treatment of inflammatory bowel disease with IFN-γ inhibitors
US5412123A (en) 1993-02-08 1995-05-02 Glycomed Incorporated Anthraquinone and anthracene derivatives as inhibitors of the cell-adhesion molecules of the immune system
JP2716657B2 (en) * 1993-02-26 1998-02-18 株式会社ディ・ディ・エス研究所 Compound having specific binding ability to adhesion molecule ELAM-1
US5763413A (en) 1993-03-04 1998-06-09 Mect Corporation Lewis-associated compound, process for producing the same, and anti-inflammatory
US5527890A (en) 1993-04-16 1996-06-18 Glycomed Incorporated Derivatives of triterpenoid acids and uses thereof
US5811404A (en) 1993-05-14 1998-09-22 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
WO1994026760A1 (en) 1993-05-14 1994-11-24 Cytel Corporation SIALYL Lex ANALOGUES AS INHIBITORS OF CELLULAR ADHESION
US5854218A (en) 1993-05-14 1998-12-29 Cytel Corporation Sialyl Lex analogues as inhibitors of cellular adhesion
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
CA2162600C (en) 1993-05-17 2000-07-11 Chrales W. Rittershaus Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5976540A (en) 1993-05-17 1999-11-02 T Cell Sciences, Inc. Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
US5646248A (en) 1993-06-08 1997-07-08 La Jolla Cancer Research Foundation E-selection binding soluble lamp-1 polypeptide
US5789385A (en) 1993-06-16 1998-08-04 Glycomed Incorporated Sialyl Lewisx mimetics containing phenyl backbones
US5750508A (en) 1993-06-16 1998-05-12 Glycomed Incorporated Sialic acid/fucose based medicaments
US5837689A (en) 1993-06-16 1998-11-17 Glycomed Incorporated Sialyl lewis-x mimetics containing naphthyl backbones
US5658880A (en) 1993-06-16 1997-08-19 Glycomed Incorporated Sialic acid/fucose based medicaments
US5679321A (en) 1993-06-17 1997-10-21 Glycomed Incorporated Sialic acid/fucose based medicaments
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5508387A (en) 1993-08-04 1996-04-16 Glycomed Incorporated Selectin binding glycopeptides
US5827837A (en) 1993-08-20 1998-10-27 The Regents Of The University Of California Polyanion anti-inflammatory agents
US5464815A (en) 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
WO1995010296A1 (en) 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5783693A (en) 1993-11-19 1998-07-21 The Regents Of The University Of California Methods for synthesizing sulfated disaccharide inhibitors of selectins
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
US5663151A (en) 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
EP0671409A3 (en) 1994-03-11 1996-06-12 Hoechst Ag Malonic acid derivatives having anti-adhesive properties.
DE4408248A1 (en) * 1994-03-11 1995-09-14 Hoechst Ag Physiologically acceptable and physiologically degradable carbohydrate mimetics, process for their preparation and their use
US5444050A (en) 1994-04-29 1995-08-22 Texas Biotechnology Corporation Binding of E-selectin or P-selectin to sialyl Lewisx or sialyl-Lewisa
HUT77345A (en) 1994-04-29 1998-03-30 Texas Biotechnology Corporation Mannopyranosyloxy biphenyl derivatives capable of inhibiting the binding of e-selectin,p-selectin or l-selectin to sialyl-lewis x or sialyl-lewis a and pharmaceutical compositions containing them
US5486536A (en) 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
JPH0899989A (en) 1994-09-30 1996-04-16 Akira Hasegawa New glycolipid derivative and intermediate for its production
DE4436164A1 (en) 1994-10-10 1996-04-11 Hoechst Ag New conjugates of tetra:carbohydrate and amide-linked peptide or dye etc.
US5686426A (en) 1994-11-17 1997-11-11 Bristol-Myers Squibb Company Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US5639734A (en) 1994-12-20 1997-06-17 Esko; Jeffrey D. Disaccharide inflammation inhibitors and uses thereof
US20020040008A1 (en) 1995-01-24 2002-04-04 Wagner Denisa D. Method for treating and preventing atherosclerosis
US5736533A (en) 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
PL324258A1 (en) * 1995-06-29 1998-05-11 Ciba Geigy Ag Diglycosiled 1,2-dioles mimetisingly acting on sialed lewis x and sialed lewis a
US5876715A (en) 1995-08-17 1999-03-02 The Biomembrane Institute Antibodies that bind novel carbohydrate ligands (myelorollins) that cause E-selectin dependent cell rolling, and uses thereof
DE19532902A1 (en) 1995-09-06 1997-03-13 Hoechst Ag Novel glycomimetics as selectin antagonists and anti-inflammatory drugs made from them
DE19537334A1 (en) 1995-10-09 1997-04-10 Hoechst Ag New piperidine carboxylic acid and pyrrolidine carboxylic acid derivs.
EP0859005A1 (en) 1995-10-26 1998-08-19 Kanebo, Ltd. Fucose derivatives, drugs containing the same as active ingredient, and intermediates for producing the same
US5747463A (en) 1995-11-13 1998-05-05 Bristol-Myers Squibb Company Malonate derivatives of glycolipids as cell adhesion inhibitors
DE19602355A1 (en) 1996-01-24 1997-07-31 Hoechst Ag Multiple fucosylated dicarboxylic acids with anti-adhesive properties
WO1997028174A1 (en) 1996-01-30 1997-08-07 Novartis Ag SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES
DE69737496D1 (en) 1996-01-30 2007-05-03 Glycomimetics Inc SIALYL-LEWISa AND SIALYL LEWISx EPITOP ANALOGUE
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
ATE217788T1 (en) 1996-03-01 2002-06-15 Univ California INHIBITION OF SELECTIN BINDING
US5654412A (en) 1996-05-29 1997-08-05 Glycomed Incorporated Processes for the synthesis of sialyl Lewisx compounds
US5994402A (en) 1996-06-05 1999-11-30 Rotstein; Ori D. Anti-inflammatory and anti-pyretic method
US5919768A (en) 1996-06-26 1999-07-06 Texas Biotechnology Corporation Di- and trivalent small molecule selectin inhibitors
US5830871A (en) 1996-10-28 1998-11-03 The Scripps Research Institute Inhibitors of E-, P- and L-selectin binding
GB9618520D0 (en) 1996-09-05 1996-10-16 Chiroscience Ltd Compounds and their therapeutic use
US6110897A (en) 1996-10-10 2000-08-29 Glycorex Ab Antiinflammatory cell adhesion inhibitors
WO1998037902A1 (en) 1997-02-28 1998-09-03 The Regents Of The University Of California Inhibition of cell-cell binding by lipid assemblies
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
SE9701127D0 (en) 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusion protein carrying GALal, 3GAL epitopes
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6193973B1 (en) 1997-08-22 2001-02-27 B. David Tuttle Dietary supplement for boosting energy and increasing muscular strength
US5948628A (en) 1997-09-05 1999-09-07 The Board Of Regents Of The University Of Oklahoma Methods of screening for compounds which mimic galectin-1
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
US6265192B1 (en) 1998-03-20 2001-07-24 The Regents Of The University Of California Glycosly sulfortransferase-3
US6365365B1 (en) 1998-03-20 2002-04-02 The Regents Of The University Of California Method of determining whether an agent modulates glycosyl sulfotransferase-3
US6037333A (en) 1998-05-07 2000-03-14 Trustees Of Tufts College Microbe-inhibiting compositions
EP1087996B1 (en) 1998-06-16 2007-01-17 The Board of Regents of The University of Oklahoma Glycosulfopeptides and methods of synthesis and use thereof
WO2000017216A1 (en) 1998-09-21 2000-03-30 Otsuka Pharmaceutical Co., Ltd. Carboxymethylgalactose derivatives
IL142864A0 (en) 1998-11-12 2002-03-10 Novolytics Inc Compositions and methods for producing vascular occlusion
CA2408883A1 (en) 2000-05-19 2001-11-29 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US20020132220A1 (en) 2000-12-27 2002-09-19 Berens Kurt L. Use of selectin antagonists in organ preservation solutions
US7087212B2 (en) 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
SI2264043T1 (en) * 2005-09-02 2018-01-31 Glycomimetics, Inc. Heterobifunctional pan-selectin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Titz, A. et al "Mimetics of silalyl Lewis x ..." Chimie (2007) vol 61, no 4, ppp 194-197. *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109002B2 (en) 2011-12-22 2015-08-18 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9796745B2 (en) 2011-12-22 2017-10-24 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US10526361B2 (en) 2011-12-22 2020-01-07 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US10766916B2 (en) 2011-12-22 2020-09-08 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11987598B2 (en) 2011-12-22 2024-05-21 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US11332491B2 (en) 2011-12-22 2022-05-17 Glycomimetics, Inc. E-selectin antagonist compounds, compositions, and methods of use
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
WO2014149837A1 (en) * 2013-03-15 2014-09-25 Glycomimetics, Inc. Compounds and methods to enhance the oral availability of glycomimetics
US10519181B2 (en) 2014-12-03 2019-12-31 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectins and CXCR4 chemokine receptors
US11045485B2 (en) * 2016-01-22 2021-06-29 Glycomimetics, Inc. Glycomimetic inhibitors of PA-IL and PA-IIL lectins
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
US11780873B2 (en) 2016-10-07 2023-10-10 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
US11197877B2 (en) 2017-03-15 2021-12-14 Glycomimetics. Inc. Galactopyranosyl-cyclohexyl derivauves as E-selectin antagonists
US11878026B2 (en) 2017-03-15 2024-01-23 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
US11712446B2 (en) 2017-11-30 2023-08-01 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
US11548908B2 (en) 2017-12-29 2023-01-10 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US11707474B2 (en) 2018-03-05 2023-07-25 Glycomimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3

Also Published As

Publication number Publication date
JP2010506832A (en) 2010-03-04
US20080161546A1 (en) 2008-07-03
EP2074132B1 (en) 2013-05-15
CA2666103A1 (en) 2008-05-22
JP5298020B2 (en) 2013-09-25
EP2074132A2 (en) 2009-07-01
JP2013189471A (en) 2013-09-26
WO2008060378A3 (en) 2008-10-02
CA2666103C (en) 2014-02-18
WO2008060378A2 (en) 2008-05-22
US7964569B2 (en) 2011-06-21

Similar Documents

Publication Publication Date Title
US7964569B2 (en) Glycomimetic replacements for hexoses and N-acetyl hexosamines
US8026222B2 (en) Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
JP5014573B2 (en) Lipid A and other carbohydrate ligand analogues
EP2755722B1 (en) Novel sglt inhibitors
US10052373B2 (en) Protein and peptide-free synthetic vaccines against Streptococcus pneumoniae type 3
JP6265985B2 (en) Multimeric mannosides, their production and use as pharmaceuticals
WO2001038338A1 (en) Synthetic oligomannosides, preparation and uses thereof
Ishiwata et al. Synthesis and TNF-α inducing activities of mycoloyl-arabinan motif of mycobacterial cell wall components
CN107709343B (en) Vaccine against streptococcus pneumoniae serotype 5
US20110112184A1 (en) Compounds with glycidic structure active in the therapy of systemic and local inflammation
EP2554549A1 (en) Oligosaccharides and oligosaccharides-protein conjugates derived from clostridium difficile polysaccharide PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools
US6759390B2 (en) Compounds and their uses
US6716826B2 (en) Compounds and their uses
US20220227801A1 (en) Tetrasaccharides for the diagnosis, prevention, and treatment of melioidosis and glanders
Zhang et al. The influence of the long chain fatty acid on the antagonistic activities of Rhizobium sin-1 lipid A
US10105380B2 (en) Glycoclusters and their pharmaceutical use as antibacterials
WO2017071152A1 (en) Phosphoryl mannose pentasaccharide and derivatives thereof, and preparation method and use thereof
Williams An adjuvant investigation: chemical synthesis and immunological evaluation of natural and unnatural archaeal lipids

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION